Professor Tessa Holyoake

  • Professor of Experimental Haematology (Paul O'Gorman Leukaemia Research Centre)

telephone: 01413017880
email: Tessa.Holyoake@glasgow.ac.uk

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • Experimental Cancer Medicine Centre (ECMC)
    Cancer Research UK
    2016 - 2017
     
  • CORE SNBTS Agreement - Tissue and Cellular Therapies Theme Group
    Scottish National Blood Transfusion Service
    2016 - 2017
     
  • Experimental Cancer Medicine Centre (ECMC)
    Scottish Executive Health Department
    2016 - 2017
     
  • Targeting CD70/27 axis in TKI treated BCR-ABL1+ CML cells with ARGX-110
    Cancer Research UK
    2016 - 2017
     
  • Targeting p53, cMyc and PRC2 regulatory hubs: A systematic and stratified approach to deliver new therapeutics for CML
    Leukaemia & Lymphoma Research
    2015 - 2020
     
  • Experimental Cancer Medicine Centre (ECMC)
    Scottish Executive Health Department
    2015 - 2016
     
  • Experimental Cancer Medicine Centre (ECMC)
    Cancer Research UK
    2015 - 2016
     
  • CORE SNBTS Agreement - Tissue and Cellular Therapies Theme Group
    Scottish National Blood Transfusion Service
    2015 - 2016
     
  • Dual targeting of p53 and c-myc to eradicate CML stem cells
    Leukaemia & Lymphoma Research
    2014 - 2016
     
  • Investigation of the role of rho kinase in the survival of chronic myeloid leukaemia cells
    Wellcome Trust
    2014 - 2016
     
  • CORE SNBTS Agreement - Tissue and Cellular Therapies Theme Group
    Scottish National Blood Transfusion Service
    2014 - 2015
     
  • Modulation of H3K27 methylation to eradicate TKI-persistant CML stem cells
    Leukaemia & Lymphoma Research
    2014 - 2017
     
  • Validating induced pluripotent stem cells (iPSC) as an acceptable model for pre-clinical drug screening in haematological malignancies
    Dr Hadwen Trust for Humane Research
    2014 - 2017
     
  • Investigation of a minor groove-binding polyamide to inhibit E2F1 in CML stem cells
    Cancer Research UK
    2014 - 2016
     
  • Experimental Cancer Medicine Centre (ECMC)
    Cancer Research UK
    2014 - 2015
     
  • Experimental Cancer Medicine Centre (ECMC)
    Scottish Executive Health Department
    2014 - 2015
     
  • Clinical research fellow in experimental haematology
    The Rockefeller Foundation
    2014 - 2016
     
  • Clinical Assessment of Transcription Factor Targeting in Chronic Myeloid Leukaemia
    Medical Research Council
    2014 - 2015
     
  • CiC: Targeting neurotransmitter pathways: identifying novel therapeutics to eradicate CML stem cells
    Medical Research Council
    2014 - 2015
     
  • Dual targeting of p53 and c-myc to eradicate CML stem cells
    Leukaemia & Lymphoma Research
    2013 - 2016
     
  • WeCan Clinical Research Fellowship
    The Beatson Institute for Cancer Research
    2013 - 2014
     
  • The importance of the Notch pathway and its interaction in the maintenance and progression of chronic myeloid leukaemia
    Wellcome Trust
    2013 - 2016
     
  • CORE SNBTS Agreement - Tissue and Cellular Therapies Theme Group
    Scottish National Blood Transfusion Service
    2013 - 2014
     
  • Experimental Cancer Medicine Centre (ECMC)
    Cancer Research UK
    2013 - 2014
     
  • Experimental Cancer Medicine Centre (ECMC)
    Scottish Executive Health Department
    2013 - 2014
     
  • Key survival pathways in chronic myeloid leukaemic (CML) stem cells and novel approaches to their eradication
    Cancer Research UK
    2013 - 2015
     
  • Investigation of the role of E2F1 in CML Leukaemic Stem Cells (LSC).
    The Kay Kendall Leukaemia Fund
    2013 - 2016
     
  • Experimental Cancer Medicine Centre (ECMC)
    Cancer Research UK
    2012 - 2013
     
  • Experimental Cancer Medicine Centre (ECMC)
    Scottish Executive Health Department
    2012 - 2013
     
  • Functional studies of autophagy for in vivo survival of CML stem cells
    Cancer Research UK
    2010 - 2012
     
  • To characterise how TKI therapy affects ROCK function in TKI-sensitive and resistant CML cells
    Cancer Research UK
    2010 - 2012
     
  • Targeting proliferating CLL cells with a novel drug delivery system
    Cancer Research UK
    2010 - 2012
     
  • Targeting autophagy as a tool to potentiate Imatinib-induced cell death in CML cells
    Kay Kendal Leukaemia Fund
    2010 - 2013
     
  • The relevance of autocrine growth factor activation to the survival and proliferation of primitive chronic myeloid leukaemia (CML) cells.
    MRC
    2010 - 2013
     
  • A randomised Phase II trial of Imatinib (IM) versus hydroxychloroquine (HCQ) with IM for patients with chronic myeloid leukaemia (CML) in cytogenic response (CyR)- CHOICES
    MRC
    2010 - 2013
     
  • Key survival pathways in chronic myeloid leukaemic (CML) stem cells and novel approaches to their eradication
    Cancer Research UK
    2010 - 2013
     
  • Investigation of the biological basis and clinical correlates of the association between EBV-associated Hodgkin lymphoma and HLA class I genotype
    The Kay Kendall Leukaemia Fund
    2009 - 2012
     
  • A phosphoproteomic investigation of key BCR-ABL mediated signally pathways in CML stem cells: where does tyrosine kinase inhibitor resistance lie?
    Leukaemia & Lymphoma Research
    2009 - 2012
     
  • An investigation of the role of FOXO transcription factors in CML stem cell quiescence and as potential targets in CML stem cell eradication.
    Scottish Executive Health Department
    2009 - 2012
     
  • Self-renewal pathway manipulation as a potential therapeutic strategy for the eradication of Chronic Myeloid Leukaemia (CML) Stem Cells
    Scottish Executive Health Department
    2009 - 2011
     
  • An investigation of the role of FOXO transcription factors in CML stem cell quiescence and as potential targets in CML stem cell eradication.
    Wellcome Trust
    2008 - 2009
     
  • Leukaemia stem cell biology
    William Thyne Centenary Fellowship
    2008 - 2010
     
  • Is survival of primitive, quiescent stem cells from patients with chronic myeloid leukaemia Bcr_Abl dependent or not?
    North Glasgow University Hospitals NHS Trust
    2008 - 2008
     
  • Mechanisms to overcome stem cell resistenace in CML [Chronic myeloid leukaemia]
    Wellcome Trust
    2007 - 2008
     
  • Identification of the mechanism of action of BMS-214662, an agent found to induce potent apoptosis of cancer stem cells
    NHS GGHB
    2007 - 2008
     
  • Leukaemia stem cell biology
    Dr Rhona Reid Charitable Trust
    2007 - 2010
     
  • Is Bcr-Able an expression relevant to the survival of cancer stem cells in chronic myeoid leukaemia
    Leukaemia & Lymphoma Research
    2007 - 2010
     
  • Is Bcr-Able expression relevant for the survival of cancer stem cells in chronic myeloid leukaemia
    MRC
    2007 - 2010
     
  • Leukaemia stem cell biology
    William Thyne Centenary Fellowship
    2006 - 2008
     
  • Leukaemia stem cell biology
    Louis & Marion Ferrar Charitable Trust
    2006 - 2011
     
  • Clinical research fellow in experimental haematology
    The Rockefeller Foundation
    2006 - 2009
     
  • An investigation of proteasome activity and inhibition in chronic myeloid leukaemia stem cells
    Leukaemia & Lymphoma Research
    2006 - 2008
     
  • UK CML Biobank
    Leukaemia & Lymphoma Research
    2006 - 2009
     
  • Western Scotland Objective 2 Programme - ERDF Application 103378, Leukaemia Research Centre Gartnavel
    Strathclyde European Partnership
    2006 - 2008
     
  • Leukaemia stem cell biology
    William Thyne Centenary Fellowship
    2005 - 2006
     
  • A pilot study of continuous imatina mesylate (IM) versus pulsed IM with or without Lenogastrim (rHu-G-CSF) in CML patients who have achieved a complete cytogenetic remission (the GIMI Study).
    Leukaemia & Lymphoma Research
    2005 - 2007
     
  • Fluorescence-activated cell sorting and analysing in studies of normal and malignant human murine haemopoiesis
    Leukaemia & Lymphoma Research
    2005 - 2008
     
  • Do transporter proteins contribute to clinical resistance to imatinib in chronic myeloid leukaemia? A combined study in Liverpool and ....
    Leukaemia & Lymphoma Research
    2004 - 2007
     
  • G-CSF intermittently with imatinib mesylate may eradicate residual leukaemic stem cells in Chronic Myeloid Leukaemia
    North Glasgow University Hospitals NHS Trust
    2004 - 2005
     
  • Novel drug combinations for eradication of Ph+/Bcr-Abl+ haemopoietic stem cells in chronic myeloid leukaemia (CML)
    MRC
    2003 - 2006
     
  • Novel drug combinations for eradication of Ph+/Bcr-Abl+ haemopoietic stem cells in chronic myeloid leukaemia (CML)
    Leukaemia Research Trust for Scotland
    2003 - 2006
     
  • An investigation of the relevance of quiescent Ph+ stem cells to eradication of chronic myeloid leukaemia
    Leukaemia & Lymphoma Research
    2003 - 2007
     
  • A determination of the cell cycle specific transcriptional profile of human haemopoietic stem cells - comparison of normal versus ......
    Scottish Executive Health Department
    2003 - 2006
     
  • A Study of the frequency & reversibility of & strategies to eradicate Quiescent Leukaemia Stem Cells in Chronic Myeloid Leukaemia
    The Kay Kendall Leukaemia Fund
    2002 - 2005
     
  • A determination of the cell cycle specific transcriptional profile of human haemopoietic stem cells: comparison of normal v leukameic .....
    Leukaemia & Lymphoma Research
    2002 - 2005
     

Additional information

Invited International Presentations

  • 2016: Houston, USA - MD Anderson Cancer Centre
  • 2016: Edinburgh, UK - MRC/University of Edinburgh Centre for Inflammation Research Seminar
  • 2016: Colorado, USA - Keystone Symposia on Molecular and Cellular Biology
  • 2015: Cadenabbia, Italy - Hinterzarten Circle on Cancer Research
  • 2015: Vienna, Austria - European Hematology Association
  • 2015: Toronto, Canada - Till and McCulloch Meeting
  • 2015: Estoril, Portugal - European Society of Haematology (Chair)
  • 2015: University of Edinburgh, UK - MRC
  • 2014: University of Cambridge, UK - Stem Cells in Medicine Symposium
  • 2014: Edinburgh, UK - Blood Club meeting
  • 2014: Milan, Italy - European Association of Hematology
  • 2014: Philadelphia, Pennsylvania, USA - European Society of Hematology
  • 2013: Portugal - European Society of Haematology
  • 2013: Rotterdam, The Netherlands - Erasmus Haematology Lecture
  • 2012: Vienna, Austria - Europeans Society of Hematology on Myeloproliferative Neoplams
  • 2012: Baltimore, Maryland, USA - European Society of Hematology
  • 2012: Amsterdam, The Netherlands - International Society Experimental Hematology
  • 2012: Amsterdam, The Netherlands - European Hematology Association
  • 2012: Glasgow, Scotland - British Society of Haematology Annual meeting
  • 2012: Vancouver, BC, Canada - AAAS annual symposium and workshop
  • 2012: Newcastle-upon-Tyne, England - CML conference, University of Newcastle
  • 2011: San Diego, California, USA - CML workshop at the American Society of Haematology
  • 2011: Stockholm, Sweden - Nordic CML symposium
  • 2011: Portugal - ESH-iCMLF International Conference
  • 2011: San Francisco, California, USA - University of California
  • 2011: Glasgow, Scotland - Beatson Institute of Cancer Research International Conference
  • 2011: Manchester, England - Paterson Institute of Cancer Research
  • 2011: London, England - European Haematology Association
  • 2011: Birmingham, England - BUSCC University Stem Cell Seminar
  • 2011: York, England - UKNSCN 4th Annual Scientific Conference, University of York
  • 2010: New York, New York, USA - Columbia University
  • 2010: Washington, DC, USA - ESH
  • 2010: Italy - DFG Meeting of the Hinterzartener Kreis, Cancer Research
  • 2010: Washington, DC, USA - American Association for Cancer Research
  • 2010: Boston, Massachusetts, USA - Infinity Pharmaceuticals, Cambridge
  • 2010: New York, New York, USA - Mt Sinai invited lecture
  • 2010: Dresden, Germany - Novartis International Advisory Board
  • 2009: Fourth International Workshop on CML and MPN
  • 2009: New Orleans Louisiana, USA - Moderator, Third Global Workshop on CML
  • 2009: London, England - LLR, GHD London
  • 2009: Germany - Cancer Research Award Symposium
  • 2009: Glasgow, Scotland - Beatson Institute, Cancer School, Autophagy & Senescence
  • 2009: Bordeaux, France - ESH-CML
  • 2009: Cambridge, England - Cambridge Institute for Medical Research, Addenbrooke’s Hospital
  • 2009: Cannes, France - EHA/ESH, Cancer Stem Cell Workshop
  • 2009: Brighton, England - BSH
  • 2007: Milan, Italy - 2nd International Workshop on Cancer Stem Cells
  • 2007: Mandelieu, France - ESH CML – biological basis of therapy
  • 2007: Glasgow, Scotland - LifeSciences 2007
  • 2007: Keystone, Colorado, USA - Keystone Symposium Cancer Stem Cells
  • 2006: York, England - BACR Conference
  • 2006: Catanazaro, Italy - EMBO, Cancer Stem Cell Workshop
  • 2006: Oxford, England - Molecular Therapeutics of Cancer, Queen's College
  • 2006: Amsterdam, The Netherlands - EHA 11th Congress
  • 2006: Dublin, Ireland - Advance in Haematology

Publications

List by: Type | Date

Jump to: 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001
Number of items: 176.

2016

Ben Batalla, I. et al. (2016) Axl blockade by BGB324 inhibits BCR-ABL tyrosine kinase inhibitor-sensitive and -resistant chronic myeloid leukemia. Clinical Cancer Research, (doi:10.1158/1078-0432.CCR-16-1930) (PMID:27856601) (Early Online Publication)

Holyoake, T. L., and Vetrie, D. (2016) The chronic myeloid leukaemia stem cell: stemming the tide of persistence. Blood, (Accepted for Publication)

Scott, M. T. et al. (2016) Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition. Cancer Discovery, 6(11), pp. 1248-1257. (doi:10.1158/2159-8290.CD-16-0263) (PMID:27630125)

Tarafdar, A. et al. (2016) CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression. Blood, (Accepted for Publication)

Zhang, B., Chu, S., Agarwal, P., Campbell, V. L., Hopcroft, L., Jørgensen, H. G., Lin, A., Gaal, K., Holyoake, T. L., and Bhatia, R. (2016) Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells. Blood, (doi:10.1182/blood-2015-11-679928) (PMID:27621307) (Early Online Publication)

Abraham, S. A., and Holyoake, T. L. (2016) Casting a NETwork instead of shooting magic bullets. Cell Cycle, (doi:10.1080/15384101.2016.1216926) (PMID:27579726) (Early Online Publication)

Sinclair, A. et al. (2016) CXCR2 and CXCL4 regulate survival and self-renewal of hematopoietic stem/progenitor cells. Blood, 128(3), pp. 371-383. (doi:10.1182/blood-2015-08-661785) (PMID:27222476)

Laidlaw, K. M.E. et al. (2016) Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia. Oncotarget, 7(32), pp. 51651-51664. (doi:10.18632/oncotarget.10541) (PMID:27438151)

Abraham, S. A. et al. (2016) Dual targeting of P53 and C-MYC induces selective elimination of leukemic stem cells. Nature, 534(7607), pp. 341-346. (doi:10.1038/nature18288) (PMID:27281222)

Vukovic, M. et al. (2016) Adult haematopoietic stem cells lacking Hif-1α self-renew normally. Blood, 127(23), pp. 2841-2846. (doi:10.1182/blood-2015-10-677138) (PMID:27060169) (PMCID:PMC4956613)

Irvine, D. A. et al. (2016) Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia. Scientific Reports, 6, 25476. (doi:10.1038/srep25476) (PMID:27157927) (PMCID:PMC4860619)

Sadovnik, I. et al. (2016) Identification of CD25 as STAT5-dependent growth-regulator of Leukemic stem cells in Ph+ CML. Clinical Cancer Research, 22(8), pp. 2051-2061. (doi:10.1158/1078-0432.CCR-15-0767) (PMID:26607600)

Schemionek, M. et al. (2016) MTSS1 is a critical epigenetically regulated tumor suppressor in CML. Leukemia, 30(4), pp. 823-830. (doi:10.1038/leu.2015.329) (PMID:26621336)

Karvela, M. et al. (2016) ATG7 regulates energy metabolism, differentiation and survival of Philadelphia chromosome-positive cells. Autophagy, 12(6), pp. 936-948. (doi:10.1080/15548627.2016.1162359) (PMID:27168493) (PMCID:PMC4922442)

Klionsky, D. J. et al. (2016) Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 8(4), pp. 445-544. (doi:10.4161/auto.19496)

2015

Vukovic, M. et al. (2015) Hif-1α and Hif-2α synergize to suppress AML development but are dispensable for disease maintenance. Journal of Experimental Medicine, 212(13), pp. 2223-2234. (doi:10.1084/jem.20150452) (PMID:26642852)

Horne, G., Jackson, L., Helgason, V., and Holyoake, T. L. (2015) Stem cell guardians – old and new perspectives in LSC biology. Current Drug Targets, 17, (doi:10.2174/1389450117666160712092944) (PMID:27411711) (Early Online Publication)

Holyoake, T., and Vetrie, D. (2015) Cancer: repositioned to kill stem cells. Nature, 525(7569), pp. 328-329. (doi:10.1038/nature15213) (PMID:26331538)

Aspinall-O'Dea, M., Pierce, A., Pellicano, F., Williamson, A. J., Scott, M. T., Walker, M. J., Holyoake, T. L., and Whetton, A. D. (2015) Antibody-based detection of protein phosphorylation status to track the efficacy of novel therapies using nanogram protein quantities from stem cells and cell lines. Nature Protocols, 10(1), pp. 149-168. (doi:10.1038/nprot.2015.007) (PMID:25521791)

Holyoake, T. L., and Helgason, G. V. (2015) Do we need more drugs for chronic myeloid leukemia? Immunological Reviews, 263(1), pp. 106-123. (doi:10.1111/imr.12234) (PMID:25510274)

Hopcroft, L. E. M., Calderhead, B., Gallipoli, P., Holyoake, T. L., and Girolami, M. A. (2015) Bayesian inference for model selection: an application to aberrant signalling pathways in chronic myeloid leukaemia. In: Markowetz, F. and Boutros, M. (eds.) Systems Genetics: Linking Phenotypes to Genotypes. Series: Cambridge series in systems genetics. Cambridge University Press, pp. 161-190. ISBN 9781107013841

2014

Davies, A. et al. (2014) Dual glutathione-S-transferase-θ1 and -μ1 gene deletions determine imatinib failure in chronic myeloid leukemia. Clinical Pharmacology and Therapeutics, 96(6), pp. 694-703. (doi:10.1038/clpt.2014.176) (PMID:25188725)

Valent, P., Sadovnik, I., Ráčil, Z., Herrmann, H., Blatt, K., Cerny-Reiterer, S., Eisenwort, G., Lion, T., Holyoake, T., and Mayer, J. (2014) DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia. European Journal of Clinical Investigation, 44(12), pp. 1239-1245. (doi:10.1111/eci.12368) (PMID:25371066)

Chen, Y., Peng, C., Abraham, S. A., Shan, Y., Guo, Z., Desouza, N., Cheloni, G., Li, D., Holyoake, T. L., and Li, S. (2014) Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival. Journal of Clinical Investigation, 124(9), pp. 3847-3862. (doi:10.1172/JCI66129) (PMID:25105362) (PMCID:PMC4151200)

Gallipoli, P., Cook, A., Rhodes, S., Hopcroft, L., Wheadon, H., Whetton, A. D., Jorgensen, H. G., Bhatia, R., and Holyoake, T. L. (2014) JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of chronic phase CML CD34+ cells in vitro and in vivo. Blood, 124(9), pp. 1492-1501. (doi:10.1182/blood-2013-12-545640) (PMID:24957147) (PMCID:PMC4148771)

Herrmann, H. et al. (2014) Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. Blood, 123(25), pp. 3951-3962. (doi:10.1182/blood-2013-10-536078) (PMID:24778155)

Pellicano, F., Mukherjee, L., and Holyoake, T. L. (2014) Concise review: cancer cells escape from oncogene addiction: understanding the mechanisms behind treatment failure for more effective targeting. Stem Cells, 32(6), pp. 1373-1379. (doi:10.1002/stem.1678) (PMID:24520002)

Abraham, S., Hopcroft, L., Bhatia, R., Koschmieder, S., Whetton, A., and Holyoake, T. (2014) Models to study chronic myeloid leukemia cancer stem cells. In: Rajasekhar, V. (ed.) Cancer Stem Cells. Wiley-Blackwell. ISBN 9781118356166 (doi:10.1002/9781118356203.ch9)

Crawford, L.J., Chan, E.T., Aujay, M., Holyoake, T., Melo, J.V., Jorgensen, H., Suresh, S., Walker, B., and Irvine, A.E. (2014) Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models. Oncogenesis, 3(3), e90. (doi:10.1038/oncsis.2014.3) (PMID:24590311) (PMCID:PMC3940921)

Pellicano, F. et al. (2014) The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors. Stem Cells, 32(9), pp. 2324-2337. (doi:10.1002/stem.1748) (PMID:24806995) (PMCID:PMC4282530)

2013

Gallipoli, P. et al. (2013) Safety and efficacy of pulsed imatinib with or without G-CSFversuscontinuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up. British Journal of Haematology, 163(5), pp. 674-676. (doi:10.1111/bjh.12532)

Gallipoli, P., Pellicano, F., Morrison, H., Laidlaw, K., Allan, E.K., Bhatia, R., Copland, M., Jorgensen, H.G., and Holyoake, T.L. (2013) Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation. Blood, 122(19), pp. 3335-3339. (doi:10.1182/blood-2013-02-485607)

Williamson, A.J.K. et al. (2013) A specific PTPRC/CD45 phosphorylation event governed by stem cell chemokine CXCL12 regulates primitive hematopoietic cell motility. Molecular and Cellular Proteomics, 12(11), pp. 3319-3329. (doi:10.1074/mcp.M112.024604)

Neviani, P. et al. (2013) PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. Journal of Clinical Investigation, 123(10), pp. 4144-4157. (doi:10.1172/JCI68951)

Guitart, A.V. et al. (2013) Hif-2 is not essential for cell-autonomous hematopoietic stem cell maintenance. Blood, 122(10), pp. 1741-1745. (doi:10.1182/blood-2013-02-484923)

Nencioni, A., Cea, M., Montecucco, F., Longo, V.D., Patrone, F., Carella, A.M., Holyoake, T.L., and Helgason, G.V. (2013) Autophagy in blood cancers: biological role and therapeutic implications. Haematologica, 98(9), pp. 1335-1343. (doi:10.3324/haematol.2012.079061)

Helgason, G.V., Mukhopadhyay, A., Karvela, M., Salomoni, P., Calabretta, B., and Holyoake, T.L. (2013) Autophagy in chronic myeloid leukaemia: stem cell survival and implication in therapy. Current Cancer Drug Targets, 13(7), pp. 724-34.

Sinclair, A., Latif, A.L., and Holyoake, T.L. (2013) Targeting survival pathways in chronic myeloid leukaemia stem cells. British Journal of Pharmacology, 169(8), pp. 1693-1707. (doi:10.1111/bph.12183)

Bolton-Gillespie, E. et al. (2013) Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood, 121(20), pp. 4175-4183. (doi:10.1182/blood-2012-11-466938)

Griaud, F., Pierce, A., Gonzalez Sanchez, M.B., Scott, M., Abraham, S.A., Holyoake, T.L., Tran, D.D.H., Tamura, T., and Whetton, A.D. (2013) A pathway from leukemogenic oncogenes and stem cell chemokines to RNA processing via THOC5. Leukemia, 27(4), pp. 932-940. (doi:10.1038/leu.2012.283)

Schachtner, H. et al. (2013) Megakaryocytes assemble podosomes that degrade matrix and protrude through basement membrane. Blood, 121(13), pp. 2542-2552. (doi:10.1182/blood-2012-07-443457)

Chen, M. et al. (2013) Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex. Journal of the National Cancer Institute, 105(6), pp. 405-423. (doi:10.1093/jnci/djt006)

Zhang, B., Li, M., McDonald, T., Holyoake, T.L., Moon, R.T., Campana, D., Shultz, L., and Bhatia, R. (2013) Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt- -catenin signaling. Blood, 121(10), pp. 1824-1838. (doi:10.1182/blood-2012-02-412890)

Giannoudis, A. et al. (2013) The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. Blood, 121(4), pp. 628-637. (doi:10.1182/blood-2012-01-405035)

Balabanov, S., Evans, C.A., Abraham, S.A., Pellicano, F., Copland, M., Walker, M.J., Whetton, A.D., and Holyoake, T.L. (2013) Quantitative proteomics analysis of BMS-214662 effects on CD34 positive cells from chronic myeloid leukaemia patients. Proteomics, 13(1), pp. 153-168. (doi:10.1002/pmic.201200022)

Abraham, S., Hopcroft, L., Carrick, E., Williamson, A., Pierce, A., Cassels, J., Pellicano, F., Whetton, A., and Holyoake, T. L. (2013) p53 and c-Myc are critical signaling hubs that maintain chronic myeloid leukemia. In: 55th American Society of Hematology Annual Meeting and Exposition, New Orleans, LA, USA, 7-10 Dec 2013, p. 1465.

Helgason, G.V., Holyoake, T.L., and Ryan, K.M. (2013) Role of autophagy in cancer prevention, development and therapy. Essays in Biochemistry, 55(1), pp. 133-151. (doi:10.1042/BSE0550133)

2012

Calaminus, S. D.J., Guitart, A., Sinclair, A., Schachtner, H., Watson, S. P., Holyoake, T. L., Kranc, K. R., and Machesky, L. M. (2012) Lineage tracing of Pf4-Cre marks hematopoietic stem cells and their progeny. PLoS ONE, 7(12), e51361. (doi:10.1371/journal.pone.0051361)

Eyre, T. et al. (2012) Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia. Blood, 120(22), pp. 4441-4443. (doi:10.1182/blood-2012-09-456517)

Eyre, T. et al. (2012) Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia. Blood, 120(22), pp. 4441-4443. (doi:10.1182/blood-2012-09-456517)

Nieborowska-Skorska, M. et al. (2012) Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood, 119(18), pp. 4253-4263. (doi:10.1182/blood-2011-10-385658)

Marenah, L., Allan, E.K., Mountford, J.C., Holyoake, T.L., Jorgensen, H.G., and Elliott, M.A. (2012) Investigation into omacetaxine solution stability for in vitro study. Biomedical Chromatography, 26(5), pp. 545-547. (doi:10.1002/bmc.1686)

Hopcroft, L.E.M., Pellicano, F., Aspinall-O'Dea, M., Whetton, A.D., and Holyoake, T.L. (2012) Abstracts: Identification of the key survival pathways underlying CML stem cell resistance to TKIs. British Journal of Haematology, 157(S1), p. 2. (doi:10.1111/j.1365-2141.2012.09071.x)

Karvela, M., Mukhopadhyay, A., Allan, E., Helgason, G.V., and Holyoake, T. (2012) Specific inhibition of autophagy enhances TKI-induced death in CML cells. British Journal of Haematology, 157(S1), p. 58. (doi:10.1111/j.1365-2141.2012.09071.x)

MacKay, C.E., Allen, E.K., Mukhopadhyay, A., Karvela, M., Holyoake, T., Jorgensen, H., and Helgason, V. (2012) Effect of BCR-ABL inhibition on induction of autophagy in chronic myeloid leukaemia cells. British Journal of Haematology, 157(S1), p. 58. (doi:10.1111/j.1365-2141.2012.09071.x)

Shah, M., Gallipoli, P., Lyons, J., Holyoake, T. L., and Jorgensen, H. (2012) Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro. Blood, Cells, Molecules and Diseases, 48(3), pp. 199-201. (doi:10.1016/j.bcmd.2012.01.005)

Karvela, M., Helgason, G. V., and Holyoake, T. L. (2012) Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Expert Review of Anticancer Therapy, 12(3), pp. 381-392. (doi:10.1586/ERA.12.10)

Hamilton, A. et al. (2012) Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood, 119(6), pp. 1501-1510. (doi:10.1182/blood-2010-12-326843)

Gallipoli, P., Jorgensen, H., and Holyoake, T.L. (2012) Modulation of TGF-β 1 induced quiescence to selectively eradicate chronic myeloid leukaemia stem cells. British Journal of Haematology, 157(S1), pp. 55-56. (doi:10.1111/j.1365-2141.2012.09071.x)

Li, L., Wang, L., Li, L., Wang, Z., Ho, Y., McDonald, T., Holyoake, T.L., Chen, W., and Bhatia, R. (2012) Activation of p53 by SIRT1 inhibition enhances elimination of CML leukaemia stem cells in combination with imatinib. Cancer Cell, 21(2), pp. 266-281. (doi:10.1016/j.ccr.2011.12.020)

Li, L., Wang, L., Li, L., Wang, Z., Ho, Y., McDonald, T., Holyoake, T.L., Chen, W., and Bhatia, R. (2012) Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell, 21(2), pp. 266-281. (doi:10.1016/j.ccr.2011.12.020)

Nieborowska-Skorska, M. et al. (2012) Rac2-mitochondrial respiratory chain complex III-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood, (doi:10.1182/blood-2011-10-385658)

Roy, S., Jorgensen, H.G., Roy, P., Abed El Baky, M., Melo, J.V., Strathdee, G., Holyoake, T.L., and Bartholomew, C. (2012) BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia. British Journal of Haematology, 157(4), pp. 446-456. (doi:10.1111/j.1365-2141.2012.09078.x)

Soliera, A.R. et al. (2012) Gfi-1 inhibits proliferation and colony formation of p210BCR/ABL-expressing cells via transcriptional repression of STAT 5 and Mcl-1. Leukemia, (doi:10.1038/leu.2012.19)

2011

Ibrahim, A.R., Clark, R.E., Holyoake, T.L., Byrne, J., Shepherd, P., Apperley, J.F., Milojkovic, D., Szydlo, R., Goldman, J., and Marin, D. (2011) Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed. Haematologica, 96(12), pp. 1779-1782. (doi:10.3324/haematol.2011.049759)

Gallipoli, P., Abraham, S. A., and Holyoake, T. L. (2011) Hurdles toward a cure for CML: the CML stem cell. Hematology/Oncology Clinics of North America, 25(5), pp. 951-966. (doi:10.1016/j.hoc.2011.09.001)

Gallipoli, P., Shepherd, P., Irvine, D., Drummond, M., and Holyoake, T. (2011) Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study. British Journal of Haematology, 155(1), pp. 128-130. (doi:10.1111/j.1365-2141.2011.08653.x)

Pellicano, F., and Holyoake, T.L. (2011) Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks. Journal of Experimental Medicine, 208(11), pp. 2155-2158. (doi:10.1084/jem.20112087)

Helgason, G. V., Karvela, M., and Holyoake, T. L. (2011) Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. Blood, 118(8), pp. 2035-2043. (doi:10.1182/blood-2011-01-330621)

Mukhopadhyay, A., Helgason, G. V., Karvela, M., and Holyoake, T. L. (2011) Hydroxychloroquine for chronic myeloid leukemia: complete cure on the horizon? Expert Review of Hematology, 4(4), pp. 369-371. (doi:10.1586/ehm.11.34)

Pellicano, F., Simara, P., Sinclair, A., Helgason, G.V., Copland, M., Grant, S., and Holyoake, T.L. (2011) The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells. Leukemia, 25(7), pp. 1159-67. (doi:10.1038/leu.2011.67)

Schmidt, T. et al. (2011) Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1+leukemia. Cancer Cell, 19(6), pp. 740-753. (doi:10.1016/j.ccr.2011.05.007)

Allan, E.K., Holyoake, T.L., Craig, A.R., and Jorgensen, H.G. (2011) Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells. Leukemia, 25(6), pp. 985-994. (doi:10.1038/leu.2011.55)

Balabanov, S. et al. (2011) Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro. PLoS ONE, 6(4), e19164.

Iqbal, Z., Elliott, M., Watson, D.G., Holyoake, T.L., and Jorgensen, H.G. (2011) Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MS. Pakistan Journal of Pharmaceutical Sciences, 24(3), pp. 285-291.

Pellicano, F., Sinclair, A., and Holyoake, T.L. (2011) In search of CML stem cells’ deadly weakness. Current Hematologic Malignancy Reports, 6(2), pp. 82-87. (doi:10.1007/s11899-011-0085-y)

Van Etten, R.A. et al. (2011) The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues. Haematologica, 96(4), pp. 590-601. (doi:10.3324/haematol.2010.035675)

2010

Zhou, P., Hatziieremia, S., Elliott, M. A., Scobie, L., Crossan, C., Michie, A. M., Holyoake, T. L., Halbert, G. W., and Jorgensen, H. G. (2010) Uptake of synthetic low density lipoprotein by leukemic stem cells — a potential stem cell targeted drug delivery strategy. Journal of Controlled Release, 148(3), pp. 380-387. (doi:10.1016/j.jconrel.2010.09.016)

Hopcroft, L. E.M., McBride, M. W., Harris, K. J., Sampson, A. K., McClure, J. D., Graham, D., Young, G., Holyoake, T. L., Girolami, M. A., and Dominiczak, A. F. (2010) Predictive response-relevant clustering of expression data provides insights into disease processes. Nucleic Acids Research, 38(20), pp. 6831-6840. (doi:10.1093/nar/gkq550)

Lidonnici, M.R. et al. (2010) Expression of the transcriptional repressor Gfi-1 is regulated by C/EBP  and is involved in its proliferation and colony formation-inhibitory effects in p210BCR/ABL-expressing cells. Cancer Research, 70(20), pp. 7949-7959. (doi:10.1158/0008-5472.CAN-10-1667)

Schemionek, M. et al. (2010) BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood, 115(16), pp. 3185-3195. (doi:10.1182/blood-2009-04-215376)

Helgason, V., Young, G., and Holyoake, T. (2010) Targeting chronic myeloid leukemia stem cells. Current Hematologic Malignancy Reports, 5(2), pp. 81-87. (doi:10.1007/s11899-010-0043-0)

Murray, J.A., Khanim, F.L., Hayden, R.E., Craddock, C.F., Holyoake, T.L., Jackson, N., Lumley, M., Bunce, C.M., and Drayson, M.T. (2010) Combined bezafibrate and medroxyprogesterone acetate have efficacy without haematological toxicity in elderly and relapsed acute myeloid leukaemia (AML). British Journal of Haematology, 149(1), pp. 65-69. (doi:10.1111/j.1365-2141.2009.08055.x)

Hamilton, A., Gallipoli, P., Nicholson, E., and Holyoake, T.L. (2010) Targeted therapy in haematological malignancies. Journal of Pathology, 220(4), pp. 404-418. (doi:10.1002/path.2669)

Szabo, S.M., Levy, A.R., Davis, C., Holyoake, T.L., and Cortes, J. (2010) A Multinational Study of Health State Preference Values Associated with Chronic Myelogenous Leukemia. Value in Health, 13(1), pp. 103-111. (doi:10.1111/j.1524-4733.2009.00573.x)

Heaney, N. B. et al. (2010) Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells. Blood, 115(11), pp. 2241-2250. (doi:10.1182/blood-2008-06-164582)

Irvine, D. A., Heaney, N. B., and Holyoake, T. L. (2010) Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors - A synthesis of clinical and laboratory data. Blood Reviews, 24(1), pp. 1-9. (doi:10.1016/j.blre.2009.11.002)

Jiang, X. et al. (2010) Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate. Blood, 116(12), pp. 2112-2121. (doi:10.1182/blood-2009-05-222471)

Saglio, G., Kantarjian, H., Holyoake, T., Ranganathan, A., and Cortés, J.E. (2010) Proceedings of the Third Global Workshop on Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 10(6), pp. 443-451. (doi:10.3816/CLML.2010.n.077)

Zhang, B. et al. (2010) Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell, 17(5), pp. 427-442. (doi:10.1016/j.ccr.2010.03.011)

2009

Holyoake, T., and Nicholson, E. (2009) The Chronic Myeloid Leukemia Stem Cell. Clinical Lymphoma, Myeloma and Leukemia, 9(Suppl.), S376-S381. (doi:10.3816/CLM.2009.s.037)

Pellicano, F., Copland, M., Jorgensen, H. G., Mountford, J., Leber, B., and Holyoake, T. L. (2009) BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cβ. Blood, 114(19), pp. 4186-4196. (doi:10.1182/blood-2009-05-219550)

Davies, A. et al. (2009) Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia, 23(11), pp. 1999-2006. (doi:10.1038/leu.2009.166)

Goldman, J.M., Green, A.R., Holyoake, T.L., Jamieson, C., Mesa, R., Mughal, T., Pellicano, F., Perrotti, D., Skoda, R., and Vannucchi, A.M. (2009) Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues. Leukemia, 23(10), pp. 1708-1715. (doi:10.1038/leu.2009.142)

Drummond, M.W. et al. (2009) A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response. Leukemia, 23(6), pp. 1199-1201. (doi:10.1038/leu.2009.43)

Hatziieremia, S., Jordanides, N.E., Holyoake, T.L., Mountford, J.C., and Jorgensen, H.G. (2009) Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib. Experimental Hematology, 37(6), pp. 692-700. (doi:10.1016/j.exphem.2009.02.006)

Allan, E.K., Hamilton, A., Hatziieremia, S., Zhou, P., Jorgensen, H.G., Vigneri, P., and Holyoake, T.L. (2009) Nuclear entrapment of BCR-ABL by combining imatinib mesylate with leptomycin B does not eliminate CD34+ chronic myeloid leukaemia cells. Leukemia, 23(5), pp. 1006-1008. (doi:10.1038/leu.2008.367)

Bellodi, C. et al. (2009) Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells. Journal of Clinical Investigation, 119(5), pp. 1109-1123. (doi:10.1172/JCI35660)

Hamilton, A., Alhashimi, F., Myssina, S., Jorgensen, H. G., and Holyoake, T. L. (2009) Optimization of methods for the detection of BCR-ABL activity in Philadelphia-positive cells. Experimental Hematology, 37(3), pp. 395-401. (doi:10.1016/j.exphem.2008.11.005)

Myssina, S. et al. (2009) Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells. Experimental Hematology, 37(2), pp. 206-214. (doi:10.1016/j.exphem.2008.10.013)

Copland, M., Michie, A. M., and Holyoake, T. L. (2009) Stem cells in Leukemia and other hematological malignancies. In: Majumder, S. (ed.) Stem Cells and Cancer. Springer New York: New York, NY, pp. 111-136. ISBN 9780387896106 (doi:10.1007/978-0-387-89611-3_5)

Foo, J., Drummond, M.W., Clarkson, B., Holyoake, T., and Michor, F. (2009) Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib. PLoS Computational Biology, 5(9), e1000503. (doi:10.1371/journal.pcbi.1000503)

2008

Konig, H., Copland, M., Chu, S., Jove, R., Holyoake, T. L., and Bhatia, R. (2008) Effects of Dasatinib on Src Kinase Activity and Downstream Intracellular Signaling in Primitive Chronic Myelogenous Leukemia Hematopoietic Cells. Cancer Research, 68(23), pp. 9624-9633. (doi:10.1158/0008-5472.CAN-08-1131)

Feldman, E. et al. (2008) On the use of Lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia, 22(9), pp. 1707-1711. (doi:10.1038/leu.2008.156)

Shepherd, P., Dhanapala, C., Maguire, C., White, J., Drummond, M., Holyoake, T., and Johnson, P. (2008) Successful use of national cancer registry data to monitor the effective use of imatinib for treating chronic myeloid leukaemia. Scottish Medical Journal, 53(3), pp. 8-12.

Heaney, N. B., Copland, M., Stewart, K., Godden, J., Parker, A. N., McQuaker, I. G., Smith, G. M., Crawley, C., Shepherd, P., and Holyoake, T. L. (2008) Complete molecular responses are achieved after reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukemia. Blood, 111(10), pp. 5252-5255. (doi:10.1182/blood-2007-10-118141)

Konig, H., Holtz, M., Modi, H., Manley, P., Holyoake, T., Forman, S., and Bhatia, R. (2008) Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia, 22(4), pp. 748-755. (doi:10.1038/sj.leu.2405086)

Copland, M., Pellicano, F., Richmond, L., Allan, E. K., Hamilton, A., Lee, F. Y., Weinmann, R., and Holyoake, T. L. (2008) BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood, 111(5), pp. 2843-2853. (doi:10.1182/blood-2007-09-112573)

Konig, H., Holyoake, T., and Bhatia, R. (2008) Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood, 111(4), pp. 2329-2338. (doi:10.1182/blood-2007-05-092056)

2007

Holyoake, T., and Copland, M. (2007) LSC defenses breached by chemical arsenal. Blood, 110(13), pp. 4138-4139.

Brazma, D., Grace, C., Howard, J., Melo, J., Holyoake, T., Apperley, J., and Nacheva, E. (2007) Genomic profile of chronic myelogenous leukemia: Imbalances associated with disease progression. Genes Chromosomes and Cancer, 46(11), pp. 1039-1050. (doi:10.1002/gcc.20487)

Jorgensen, H.G., and Holyoake, T.L. (2007) Characterization of cancer stem cells in chronic myeloid leukaemia. Biochemical Society Transactions, 35(5), pp. 1347-1351. (doi:10.1042/BST0351347)

Strathdee, G. et al. (2007) Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clinical Cancer Research, 13(17), pp. 5048-5055. (doi:10.1158/1078-0432.CCR-07-0919)

Drummond, M., Balabanov, S., Holyoake, T., and Brummendorf, T. (2007) Concise review: Telomere biology in normal and leukemic hematopoietic stem cells. Stem Cells, 25(8), pp. 1853-1861. (doi:10.1634/stemcells.2007-0057)

Griffiths, S., Burthem, J., Unwin, R., Holyoake, T., Melo, J., Lucas, G., and Whetton, A. (2007) The use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia. Molecular Biotechnology, 36(2), pp. 81-89. (doi:10.1007/s12033-007-0005-5)

Heaney, N., and Holyoake, T. (2007) Therapeutic targets in chronic myeloid leukaemia. Hematological Oncology, 25(2), pp. 66-75. (doi:10.1002/hon.813)

Allan, E.K., Holyoake, T.L., Jordanides, N.E., Jorgensen, H.G., and Mountford, J.C. (2007) Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood, 109(9), pp. 4016-4019. (doi:10.1182/blood-2006-11-057521)

Halsey, C., Fisher, C., Strathdee, G., Gibson, B., Holyoake, T., Vyas, P., and Graham, G. (2007) GATA1 mutational analysis in chronic myeloid leukaemia. British Journal of Haematology, 137(4), pp. 375-376. (doi:10.1111/j.1365-2141.2007.06563.x) (PMID:17408401)

McLintock, L.A., Cook, G., Holyoake, T., Jones, B.L., Kinsey, S.E., and Jackson, G.H. (2007) High loading dose AmBisome (R) is efficacious and well tolerated in the management of invasive fungal infection in hematology patients. Haematologica: The Hematology Journal, 92(4), pp. 572-573. (doi:10.3324/haematol.10531)

Balabanov, S. et al. (2007) Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach. Blood, 109(4), pp. 1701-1711. (doi:10.1182/blood-2005-03-037648)

Copland, M., Hamilton, A., and Holyoake, T. (2007) Conventional Western blotting techniques will not reliably quantify p210 BCR-ABL - Response. Blood, 109(3), p. 1336. (doi:/10.1182/blood-2006-10-050799)

Heaney, N., and Holyoake, T. (2007) What is new in chronic myeloid leukaemia? Scottish Medical Journal, 52(1), pp. 36-41.

Graham, S., Vass, J., Holyoake, T., and Graham, G. (2007) Transcriptional analysis of quiescent and proliferating CD34+human hemopoietic cells from normal and chronic myeloid leukemia sources. Stem Cells, 25(12), pp. 3111-3120. (doi:10.1634/stemcells.2007-0250)

Pellicano, F., and Holyoake, T. (2007) Stem cells in chronic myeloid leukaemia. Cancer Biomarkers, 3(4-5), pp. 183-191.

Strathdee, G., Sim, A., Soutar, R., Holyoake, T., and Brown, R. (2007) HOXA5 is targeted by cell-type-specific CpG island methylation in normal cells and during the development of acute myeloid leukaemia. Carcinogenesis, 28(2), pp. 299-309. (doi:10.1093/carcin/bgl133)

2006

Allan, E.K., Holyoake, T.L., and Jorgensen, H.G. (2006) Human neutrophil elastase is not a target for therapy in chronic myeloid leukaemia. Leukemia, 20(11), pp. 2054-2055. (doi:10.1038/sj.leu.2404411)

Fraser, A., Cook, G., Franklin, I., Templeton, J., Campbell, M., Holyoake, T., and Campbell, J. (2006) Immature monocytes from G-CSF-mobilized peripheral blood stem cell collections carry surface-bound IL-10 and have the potential to modulate alloreactivity. Journal of Leukocyte Biology, 80(4), pp. 862-869. (doi:10.1189/jlb.0605297)

Holyoake, T.L., Jordanides, N., Jorgensen, H.G., and Mountford, J.C. (2006) Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood, 108(4), pp. 1370-1373. (doi:10.1182/blood-2006-02-003145)

White, P. et al. (2006) A consensus on fungal polymerase chain reaction diagnosis? A United Kingdom Ireland evaluation of polymerase chain reaction methods for detection of systemic fungal infections. Journal of Molecular Diagnostics, 8(3), pp. 376-384. (doi:10.2353/jmoldx.2006.050120)

Copland, M., Hamilton, A., Eirick, L., Baird, J., Allan, E., Jordanides, N., Barow, M., Mountford, J., and Holyoake, T. (2006) Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood, 107(11), pp. 4532-4539. (doi:10.1182/blood-2005-07-2947)

Hamilton, A., Elrick, L., Myssina, S., Copland, M., Jorgensen, H.G., Melo, J.V., and Holyoake, T.L. (2006) BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry. Leukemia, 20(6), pp. 1035-1039. (doi:10.1038/sj.leu.2404189)

Jorgensen, H.G., Copland, M., Allan, E.K., Jiang, X.Y., Eaves, A., Eaves, C., and Holyoake, T.L. (2006) Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clinical Cancer Research, 12(2), pp. 626-633. (doi:10.1158/1078-0432.CCR-05-0429)

2005

Cummins, M. et al. (2005) Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the clinical trials committee of the British Society of Blood & Marrow Transplantation (BSBMT). Bone Marrow Transplantation, 36(12), pp. 1065-1069. (doi:10.1038/sj.bmt.1705180)

Copland, M., Jorgensen, H.G., and Holyoake, T.L. (2005) Evolving molecular therapy for chronic myeloid leukaemia - are we on target? Hematology, 10(5), pp. 349-359. (doi:10.1080/10245330500234195)

Jorgensen, H.G., Allan, E.K., Mountford, J.C., Richmond, L., Harrison, S., Elliott, M.A., and Holyoake, T.L. (2005) Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate. Experimental Hematology, 33(10), pp. 1140-1146. (doi:10.1016/j.exphem.2005.05.020)

Allan, E.K., Eaves, C.J., Elliott, M.A., Godden, J.L., Graham, S.M., Holyoake, T.L., Jorgensen, H.G., Mountford, J.C., and Richmond, L. (2005) Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia, 19(7), pp. 1184-1191. (doi:10.1038/sj.leu.2403785)

Copland, M., Fraser, A., Harrison, S., and Holyoake, T. (2005) Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia. Cancer Immunology Immunotherapy, 54(4), pp. 297-306. (doi:10.1007/s00262-004-0573-1)

Deininger, M., and Holyoake, T. (2005) Can we afford to let sleeping dogs lie? Blood, 105(5), pp. 1840-1841. (doi:10.1182/blood-2004-12-4764)

Eisterer, W. et al. (2005) Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia, 19(3), pp. 435-441. (doi:10.1038/sj.leu.2403649)

Elrick, L.J., Holyoake, T.L., Jorgensen, H.G., and Mountford, J.C. (2005) Punish the parent not the progeny. Blood, 105(5), pp. 1862-1866. (doi:10.1182/blood-2004-08-3373)

Allan, E., Jordanides, N., McLintock, L., Copland, M., Devaney, M., Stewart, K., Parker, A., Johnson, P., Holyoake, T., and Jones, B. (2005) Poor performance of galactomannan and mannan sandwich enzyme-linked immunosorbent assays in the diagnosis of invasive fungal infection. British Journal of Haematology, 128(4), pp. 578-579. (doi:10.1111/j.1365-2141.2004.05333.x)

Jordanides, N., Allan, E., McLintock, L., Copland, M., Devaney, M., Stewart, K., Parker, A., Johnson, P., Holyoake, T., and Jones, B. (2005) A prospective study of real-time panfungal PCR for the early diagnosis of invasive fungal infection in haemato-oncology patients. Bone Marrow Transplantation, 35(4), pp. 389-395. (doi:10.1038/sj.bmt.1704768)

Jorgensen, H.G., Copland, M., and Holyoake, T. (2005) Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia. Cancer, 103(1), pp. 210-211. (doi:10.1002/cncr.20742)

Kilpatrick, D., Stewart, K., Allan, E., McLintock, L., Holyoake, T., and Turner, M. (2005) Successful haemopoietic stem cell transplantation does not correct mannan-binding lectin deficiency. Bone Marrow Transplantation, 35(2), pp. 179-181. (doi:10.1038/sj.bmt.1704746)

Drummond, M.W., Hoare, S.F., Monaghan, A., Graham, S.M., Alcorn, M.J., Keith, W.N., and Holyoake, T.L. (2005) Dysregulated expression of the major telomerase components in leukaemic stem cells. Leukemia, 19(3), pp. 381-389. (doi:10.1038/sj.leu.2403616)

Jorgensen, H.G., and Holyoake, T.L. (2005) From paradigm to paradox, ponder anew the CML stem cell. Bloodmed Com,

2004

Drummond, M., Lennard, A., Brummendorf, T., and Holyoake, T. (2004) Telomere shortening correlates with prognostic score at diagnosis and proceeds rapidly during progression of chronic myeloid leukemia. Leukemia and Lymphoma, 45(9), pp. 1775-1781. (doi:10.1080/10428190410001693542)

Harrison, S., Johnson, P., and Holyoake, T. (2004) The Scotland Leukaemia Registry audit of incidence, diagnosis and clinical management of new patients with chronic myeloid leukaemia in 1999 and 2000. Scottish Medical Journal, 49(3), pp. 87-90.

Osborne, W., Holyoake, T., McQuaker, I., and Parker, A. (2004) Fatal peripheral neuropathy following FLA chemotherapy. Clinical and Laboratory Haematology, 26(4), pp. 295-296. (doi:10.1111/j.1365-2257.2004.00613.x)

McLintock, L., Holyoake, T., and Jones, B. (2004) Published rather than proposed definitions for invasive fungal infection must be applied to allow standardization in clinical trials. Clinical Infectious Diseases, 38(11), pp. 1648-1649. (doi:10.1086/421029)

McLintock, L., Jordanides, N., Allan, E., Copland, M., Stewart, K., Parker, A., Devaney, M., Holyoake, T., and Jones, B. (2004) The use of a risk group stratification in the management of invasive fungal infection: a prospective validation. British Journal of Haematology, 124(3), pp. 403-404. (doi:10.1046/j.1365-2141.2003.04794.x)

2003

Drummond, M., Marin, D., Clark, R., Byrne, J., Holyoake, T., and Lennard, A. (2003) Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission. British Journal of Haematology, 123(3), pp. 479-483. (doi:10.1046/j.1365-2141.2003.04599.x)

Kilpatrick, D.C. et al. (2003) No strong relationship between mannan binding lectin or plasma ficolins and chemotherapy-related infections. Clinical and Experimental Immunology, 134(2), pp. 279-284. (doi:10.1046/j.1365-2249.2003.02284.x)

Drummond, M., and Holyoake, T. (2003) Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer, 98(8), pp. 1776-1777. (doi:10.1002/cncr.11715)

Jorgensen, H.G., Allan, E.K., Jiang, X., Liakopoulou, E., Richmond, L., Eaves, C.J., Eaves, A.C., and Holyoake, T.L. (2003) Stage-specific alterations in serum levels of G-CSF in chronic myeloid leukaemia. Leukemia, 17(7), pp. 1430-1432. (doi:10.1038/sj.leu.2402967)

Paterson, S.C., Smith, K.D., Holyoake, T.L., and Jorgensen, H.G. (2003) Is there a cloud in the silver lining for imatinib? British Journal of Cancer, 88(7), pp. 983-987. (doi:10.1038/sj.bjc.6600828)

Chee, Y., Vickers, M., Stevenson, D., Holyoake, T., and Culligan, J. (2003) Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones. Leukemia, 17(3), pp. 634-635. (doi:10.1038/si.leu.2402842)

Drummond, A., Micallef-Eynaud, P., Douglas, W., Murphy, J., Hay, I., Holyoake, T., and Drummond, M. (2003) A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec (R)). British Journal of Haematology, 120(5), pp. 911-913. (doi:10.1046/j.1365-2141.2003.04151_4.x)

Drummond, M., Lush, C., Vickers, M., Reid, F., Kaeda, J., and Holyoake, T. (2003) Imatinib mesylate-induced molecular remission of Philadelphia chromosome-positive myelodysplastic syndrome. Leukemia, 17(2), pp. 463-465. (doi:10.1038/sj.leu.2402814)

Clark, A.D., Jorgensen, H.G., Mountford, J.C., and Holyoake, T.L. (2003) Isolation and therapeutic potential of human haemopoietic stem cells. Cytotechnology, 41(2-3), pp. 111-131. (doi:10.1023/A:1024822722285)

2002

Drummond, M., Hendry, L., Maher, E., and Holyoake, T. (2002) BCR-ABL fish monitoring of CML: A survey of current UK practice. British Journal of Haematology, 119(1), pp. 272-273. (doi:10.1046/j.1365-2141.2002.38802.x)

Richmond, L., Alcorn, M., Pearson, C., Cameron, G., Thomas, T., Eaves, C., Eaves, A., and Holyoake, T. (2002) CML leukapheresis products can be enriched for CD34(+) cells and simultaneously depleted of CD15(+) cells using a simple Ab cocktail. Cytotherapy, 4(5), pp. 407-413. (doi:10.1080/146532402320775991)

Jorgensen, H.G., Elliott, M., Paterson, S., Holyoake, T.L., and Smith, K. (2002) Further observations on the debated ability of AGP to bind imatinib - Response. Blood, 100(1), pp. 368-369.

Goldman, J., Apperley, J., Clark, R., Green, T., Holyoake, T., O'Brien, S., and Shepherd, P. (2002) Not So Nice for CML. Lancet, 359(9322), p. 2036. (doi:10.1016/S0140-6736(02)08796-2)

Holyoake, T., Jiang, X., Drummond, M., Eaves, A., and Eaves, C. (2002) Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia. Leukemia, 16(4), pp. 549-558. (doi:10.1038/sj/leu/2402444)

Pottinger, B., Walker, M., Campbell, M., Holyoake, T., Franklin, I., and Cook, G. (2002) The storage and re-infusion of autologous blood and BM as back-up following failed primary hematopoietic stem-cell transplantation: a survey of European practice. Cytotherapy, 4(2), pp. 127-135. (doi:10.1080/146532402317381839)

Graham, S.M., Jorgensen, H.G., Allan, E.K., Pearson, C., Alcorn, M.J., Richmond, L., and Holyoake, T.L. (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood, 99(1), pp. 319-325. (doi:10.1182/blood.V99.1.319)

Jorgensen, H.G., Elliott, M.A., Allan, E.K., Carr, C.E., Holyoake, T.L., and Smith, K.D. (2002) α1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. Blood, 99(2), pp. 713-715. (doi:10.1182/blood.V99.2.713)

2001

Jorgensen, H.G., and Holyoake, T.L. (2001) A comparison of normal and leukemic stem cell biology in chronic myeloid leukemia. Hematological Oncology, 19(3), pp. 89-106. (doi:10.1002/hon.667.abs)

Holyoake, T., Freshney, M., Samuel, K., Ansell, J., Watson, G., Wright, E., Graham, G., and Pragnell, I. (2001) In vivo expansion of the endogenous B-cell compartment stimulated by radiation and serial bone marrow transplantation induces B-cell leukaemia in mice. British Journal of Haematology, 114(1), pp. 49-56. (doi:10.1046/j.1365-2141.2001.02903.x)

Drummond, M., and Holyoake, T. (2001) Tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia: so far so good? Blood Reviews, 15(2), pp. 85-95. (doi:10.1054/blre.2001.0152)

Holyoake, T. (2001) Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: Lessons to be learned from the laboratory. British Journal of Haematology, 113(1), pp. 11-23. (doi:10.1046/j.1365-2141.2001.02558.x)

Campbell, J., Cook, G., and Holyoake, T. (2001) Evolution of bone marrow transplantation - the original immunotherapy. Trends in Immunology, 22(2), pp. 88-92. (doi:10.1016/S1471-4906(00)01857-3)

Holyoake, T.L., Jiang, X.Y., Jorgensen, H.G., Graham, S., Alcorn, M.J., Laird, C., Eaves, A.C., and Eaves, C.J. (2001) Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood, 97(3), pp. 720-728. (doi:10.1182/blood.V97.3.720)

Glimm, H., Eisterer, W., Lee, K., Cashman, J., Holyoake, T., Nicolini, F., Shultz, L., von Kalle, C., and Eaves, C. (2001) Previously undetected human hematopoietic cell populations with short-term repopulating activity selectively engraft NOD/SCID-beta 2 microglobulin-null mice. Journal of Clinical Investigation, 107(2), pp. 199-206. (doi:10.1172/JCI11519)

Brummendorf, T., Rufer, N., Holyoake, T., Maciejewski, J., Barnett, M., Eaves, C., Eaves, A., Young, N., and Lansdorp, P. (2001) Telomere length dynamics in normal individuals and in patients with hematopoietic stem cell-associated disorders. In: Orlic, D., Brummendorf, T., Sharkis, S. and Kanz, L. (eds.) Hematopoietic Stem Cells 2000 Basic And Clinical Sciences. Series: Annals Of The New York Academy Of Sciences (938). New York Academy of Sciences: New York, pp. 293-304. ISBN 1-57331-295-9

This list was generated on Sun Dec 4 20:31:06 2016 GMT.
Number of items: 176.

Articles

Ben Batalla, I. et al. (2016) Axl blockade by BGB324 inhibits BCR-ABL tyrosine kinase inhibitor-sensitive and -resistant chronic myeloid leukemia. Clinical Cancer Research, (doi:10.1158/1078-0432.CCR-16-1930) (PMID:27856601) (Early Online Publication)

Holyoake, T. L., and Vetrie, D. (2016) The chronic myeloid leukaemia stem cell: stemming the tide of persistence. Blood, (Accepted for Publication)

Scott, M. T. et al. (2016) Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition. Cancer Discovery, 6(11), pp. 1248-1257. (doi:10.1158/2159-8290.CD-16-0263) (PMID:27630125)

Tarafdar, A. et al. (2016) CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression. Blood, (Accepted for Publication)

Zhang, B., Chu, S., Agarwal, P., Campbell, V. L., Hopcroft, L., Jørgensen, H. G., Lin, A., Gaal, K., Holyoake, T. L., and Bhatia, R. (2016) Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells. Blood, (doi:10.1182/blood-2015-11-679928) (PMID:27621307) (Early Online Publication)

Abraham, S. A., and Holyoake, T. L. (2016) Casting a NETwork instead of shooting magic bullets. Cell Cycle, (doi:10.1080/15384101.2016.1216926) (PMID:27579726) (Early Online Publication)

Sinclair, A. et al. (2016) CXCR2 and CXCL4 regulate survival and self-renewal of hematopoietic stem/progenitor cells. Blood, 128(3), pp. 371-383. (doi:10.1182/blood-2015-08-661785) (PMID:27222476)

Laidlaw, K. M.E. et al. (2016) Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia. Oncotarget, 7(32), pp. 51651-51664. (doi:10.18632/oncotarget.10541) (PMID:27438151)

Abraham, S. A. et al. (2016) Dual targeting of P53 and C-MYC induces selective elimination of leukemic stem cells. Nature, 534(7607), pp. 341-346. (doi:10.1038/nature18288) (PMID:27281222)

Vukovic, M. et al. (2016) Adult haematopoietic stem cells lacking Hif-1α self-renew normally. Blood, 127(23), pp. 2841-2846. (doi:10.1182/blood-2015-10-677138) (PMID:27060169) (PMCID:PMC4956613)

Irvine, D. A. et al. (2016) Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia. Scientific Reports, 6, 25476. (doi:10.1038/srep25476) (PMID:27157927) (PMCID:PMC4860619)

Sadovnik, I. et al. (2016) Identification of CD25 as STAT5-dependent growth-regulator of Leukemic stem cells in Ph+ CML. Clinical Cancer Research, 22(8), pp. 2051-2061. (doi:10.1158/1078-0432.CCR-15-0767) (PMID:26607600)

Schemionek, M. et al. (2016) MTSS1 is a critical epigenetically regulated tumor suppressor in CML. Leukemia, 30(4), pp. 823-830. (doi:10.1038/leu.2015.329) (PMID:26621336)

Karvela, M. et al. (2016) ATG7 regulates energy metabolism, differentiation and survival of Philadelphia chromosome-positive cells. Autophagy, 12(6), pp. 936-948. (doi:10.1080/15548627.2016.1162359) (PMID:27168493) (PMCID:PMC4922442)

Klionsky, D. J. et al. (2016) Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 8(4), pp. 445-544. (doi:10.4161/auto.19496)

Vukovic, M. et al. (2015) Hif-1α and Hif-2α synergize to suppress AML development but are dispensable for disease maintenance. Journal of Experimental Medicine, 212(13), pp. 2223-2234. (doi:10.1084/jem.20150452) (PMID:26642852)

Horne, G., Jackson, L., Helgason, V., and Holyoake, T. L. (2015) Stem cell guardians – old and new perspectives in LSC biology. Current Drug Targets, 17, (doi:10.2174/1389450117666160712092944) (PMID:27411711) (Early Online Publication)

Holyoake, T., and Vetrie, D. (2015) Cancer: repositioned to kill stem cells. Nature, 525(7569), pp. 328-329. (doi:10.1038/nature15213) (PMID:26331538)

Aspinall-O'Dea, M., Pierce, A., Pellicano, F., Williamson, A. J., Scott, M. T., Walker, M. J., Holyoake, T. L., and Whetton, A. D. (2015) Antibody-based detection of protein phosphorylation status to track the efficacy of novel therapies using nanogram protein quantities from stem cells and cell lines. Nature Protocols, 10(1), pp. 149-168. (doi:10.1038/nprot.2015.007) (PMID:25521791)

Holyoake, T. L., and Helgason, G. V. (2015) Do we need more drugs for chronic myeloid leukemia? Immunological Reviews, 263(1), pp. 106-123. (doi:10.1111/imr.12234) (PMID:25510274)

Davies, A. et al. (2014) Dual glutathione-S-transferase-θ1 and -μ1 gene deletions determine imatinib failure in chronic myeloid leukemia. Clinical Pharmacology and Therapeutics, 96(6), pp. 694-703. (doi:10.1038/clpt.2014.176) (PMID:25188725)

Valent, P., Sadovnik, I., Ráčil, Z., Herrmann, H., Blatt, K., Cerny-Reiterer, S., Eisenwort, G., Lion, T., Holyoake, T., and Mayer, J. (2014) DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia. European Journal of Clinical Investigation, 44(12), pp. 1239-1245. (doi:10.1111/eci.12368) (PMID:25371066)

Chen, Y., Peng, C., Abraham, S. A., Shan, Y., Guo, Z., Desouza, N., Cheloni, G., Li, D., Holyoake, T. L., and Li, S. (2014) Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival. Journal of Clinical Investigation, 124(9), pp. 3847-3862. (doi:10.1172/JCI66129) (PMID:25105362) (PMCID:PMC4151200)

Gallipoli, P., Cook, A., Rhodes, S., Hopcroft, L., Wheadon, H., Whetton, A. D., Jorgensen, H. G., Bhatia, R., and Holyoake, T. L. (2014) JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of chronic phase CML CD34+ cells in vitro and in vivo. Blood, 124(9), pp. 1492-1501. (doi:10.1182/blood-2013-12-545640) (PMID:24957147) (PMCID:PMC4148771)

Herrmann, H. et al. (2014) Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. Blood, 123(25), pp. 3951-3962. (doi:10.1182/blood-2013-10-536078) (PMID:24778155)

Pellicano, F., Mukherjee, L., and Holyoake, T. L. (2014) Concise review: cancer cells escape from oncogene addiction: understanding the mechanisms behind treatment failure for more effective targeting. Stem Cells, 32(6), pp. 1373-1379. (doi:10.1002/stem.1678) (PMID:24520002)

Crawford, L.J., Chan, E.T., Aujay, M., Holyoake, T., Melo, J.V., Jorgensen, H., Suresh, S., Walker, B., and Irvine, A.E. (2014) Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models. Oncogenesis, 3(3), e90. (doi:10.1038/oncsis.2014.3) (PMID:24590311) (PMCID:PMC3940921)

Pellicano, F. et al. (2014) The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors. Stem Cells, 32(9), pp. 2324-2337. (doi:10.1002/stem.1748) (PMID:24806995) (PMCID:PMC4282530)

Gallipoli, P. et al. (2013) Safety and efficacy of pulsed imatinib with or without G-CSFversuscontinuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up. British Journal of Haematology, 163(5), pp. 674-676. (doi:10.1111/bjh.12532)

Gallipoli, P., Pellicano, F., Morrison, H., Laidlaw, K., Allan, E.K., Bhatia, R., Copland, M., Jorgensen, H.G., and Holyoake, T.L. (2013) Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation. Blood, 122(19), pp. 3335-3339. (doi:10.1182/blood-2013-02-485607)

Williamson, A.J.K. et al. (2013) A specific PTPRC/CD45 phosphorylation event governed by stem cell chemokine CXCL12 regulates primitive hematopoietic cell motility. Molecular and Cellular Proteomics, 12(11), pp. 3319-3329. (doi:10.1074/mcp.M112.024604)

Neviani, P. et al. (2013) PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. Journal of Clinical Investigation, 123(10), pp. 4144-4157. (doi:10.1172/JCI68951)

Guitart, A.V. et al. (2013) Hif-2 is not essential for cell-autonomous hematopoietic stem cell maintenance. Blood, 122(10), pp. 1741-1745. (doi:10.1182/blood-2013-02-484923)

Nencioni, A., Cea, M., Montecucco, F., Longo, V.D., Patrone, F., Carella, A.M., Holyoake, T.L., and Helgason, G.V. (2013) Autophagy in blood cancers: biological role and therapeutic implications. Haematologica, 98(9), pp. 1335-1343. (doi:10.3324/haematol.2012.079061)

Helgason, G.V., Mukhopadhyay, A., Karvela, M., Salomoni, P., Calabretta, B., and Holyoake, T.L. (2013) Autophagy in chronic myeloid leukaemia: stem cell survival and implication in therapy. Current Cancer Drug Targets, 13(7), pp. 724-34.

Sinclair, A., Latif, A.L., and Holyoake, T.L. (2013) Targeting survival pathways in chronic myeloid leukaemia stem cells. British Journal of Pharmacology, 169(8), pp. 1693-1707. (doi:10.1111/bph.12183)

Bolton-Gillespie, E. et al. (2013) Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood, 121(20), pp. 4175-4183. (doi:10.1182/blood-2012-11-466938)

Griaud, F., Pierce, A., Gonzalez Sanchez, M.B., Scott, M., Abraham, S.A., Holyoake, T.L., Tran, D.D.H., Tamura, T., and Whetton, A.D. (2013) A pathway from leukemogenic oncogenes and stem cell chemokines to RNA processing via THOC5. Leukemia, 27(4), pp. 932-940. (doi:10.1038/leu.2012.283)

Schachtner, H. et al. (2013) Megakaryocytes assemble podosomes that degrade matrix and protrude through basement membrane. Blood, 121(13), pp. 2542-2552. (doi:10.1182/blood-2012-07-443457)

Chen, M. et al. (2013) Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex. Journal of the National Cancer Institute, 105(6), pp. 405-423. (doi:10.1093/jnci/djt006)

Zhang, B., Li, M., McDonald, T., Holyoake, T.L., Moon, R.T., Campana, D., Shultz, L., and Bhatia, R. (2013) Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt- -catenin signaling. Blood, 121(10), pp. 1824-1838. (doi:10.1182/blood-2012-02-412890)

Giannoudis, A. et al. (2013) The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. Blood, 121(4), pp. 628-637. (doi:10.1182/blood-2012-01-405035)

Balabanov, S., Evans, C.A., Abraham, S.A., Pellicano, F., Copland, M., Walker, M.J., Whetton, A.D., and Holyoake, T.L. (2013) Quantitative proteomics analysis of BMS-214662 effects on CD34 positive cells from chronic myeloid leukaemia patients. Proteomics, 13(1), pp. 153-168. (doi:10.1002/pmic.201200022)

Helgason, G.V., Holyoake, T.L., and Ryan, K.M. (2013) Role of autophagy in cancer prevention, development and therapy. Essays in Biochemistry, 55(1), pp. 133-151. (doi:10.1042/BSE0550133)

Calaminus, S. D.J., Guitart, A., Sinclair, A., Schachtner, H., Watson, S. P., Holyoake, T. L., Kranc, K. R., and Machesky, L. M. (2012) Lineage tracing of Pf4-Cre marks hematopoietic stem cells and their progeny. PLoS ONE, 7(12), e51361. (doi:10.1371/journal.pone.0051361)

Eyre, T. et al. (2012) Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia. Blood, 120(22), pp. 4441-4443. (doi:10.1182/blood-2012-09-456517)

Eyre, T. et al. (2012) Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia. Blood, 120(22), pp. 4441-4443. (doi:10.1182/blood-2012-09-456517)

Nieborowska-Skorska, M. et al. (2012) Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood, 119(18), pp. 4253-4263. (doi:10.1182/blood-2011-10-385658)

Marenah, L., Allan, E.K., Mountford, J.C., Holyoake, T.L., Jorgensen, H.G., and Elliott, M.A. (2012) Investigation into omacetaxine solution stability for in vitro study. Biomedical Chromatography, 26(5), pp. 545-547. (doi:10.1002/bmc.1686)

Hopcroft, L.E.M., Pellicano, F., Aspinall-O'Dea, M., Whetton, A.D., and Holyoake, T.L. (2012) Abstracts: Identification of the key survival pathways underlying CML stem cell resistance to TKIs. British Journal of Haematology, 157(S1), p. 2. (doi:10.1111/j.1365-2141.2012.09071.x)

Karvela, M., Mukhopadhyay, A., Allan, E., Helgason, G.V., and Holyoake, T. (2012) Specific inhibition of autophagy enhances TKI-induced death in CML cells. British Journal of Haematology, 157(S1), p. 58. (doi:10.1111/j.1365-2141.2012.09071.x)

MacKay, C.E., Allen, E.K., Mukhopadhyay, A., Karvela, M., Holyoake, T., Jorgensen, H., and Helgason, V. (2012) Effect of BCR-ABL inhibition on induction of autophagy in chronic myeloid leukaemia cells. British Journal of Haematology, 157(S1), p. 58. (doi:10.1111/j.1365-2141.2012.09071.x)

Shah, M., Gallipoli, P., Lyons, J., Holyoake, T. L., and Jorgensen, H. (2012) Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro. Blood, Cells, Molecules and Diseases, 48(3), pp. 199-201. (doi:10.1016/j.bcmd.2012.01.005)

Karvela, M., Helgason, G. V., and Holyoake, T. L. (2012) Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Expert Review of Anticancer Therapy, 12(3), pp. 381-392. (doi:10.1586/ERA.12.10)

Hamilton, A. et al. (2012) Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood, 119(6), pp. 1501-1510. (doi:10.1182/blood-2010-12-326843)

Gallipoli, P., Jorgensen, H., and Holyoake, T.L. (2012) Modulation of TGF-β 1 induced quiescence to selectively eradicate chronic myeloid leukaemia stem cells. British Journal of Haematology, 157(S1), pp. 55-56. (doi:10.1111/j.1365-2141.2012.09071.x)

Li, L., Wang, L., Li, L., Wang, Z., Ho, Y., McDonald, T., Holyoake, T.L., Chen, W., and Bhatia, R. (2012) Activation of p53 by SIRT1 inhibition enhances elimination of CML leukaemia stem cells in combination with imatinib. Cancer Cell, 21(2), pp. 266-281. (doi:10.1016/j.ccr.2011.12.020)

Li, L., Wang, L., Li, L., Wang, Z., Ho, Y., McDonald, T., Holyoake, T.L., Chen, W., and Bhatia, R. (2012) Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell, 21(2), pp. 266-281. (doi:10.1016/j.ccr.2011.12.020)

Nieborowska-Skorska, M. et al. (2012) Rac2-mitochondrial respiratory chain complex III-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood, (doi:10.1182/blood-2011-10-385658)

Roy, S., Jorgensen, H.G., Roy, P., Abed El Baky, M., Melo, J.V., Strathdee, G., Holyoake, T.L., and Bartholomew, C. (2012) BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia. British Journal of Haematology, 157(4), pp. 446-456. (doi:10.1111/j.1365-2141.2012.09078.x)

Soliera, A.R. et al. (2012) Gfi-1 inhibits proliferation and colony formation of p210BCR/ABL-expressing cells via transcriptional repression of STAT 5 and Mcl-1. Leukemia, (doi:10.1038/leu.2012.19)

Ibrahim, A.R., Clark, R.E., Holyoake, T.L., Byrne, J., Shepherd, P., Apperley, J.F., Milojkovic, D., Szydlo, R., Goldman, J., and Marin, D. (2011) Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed. Haematologica, 96(12), pp. 1779-1782. (doi:10.3324/haematol.2011.049759)

Gallipoli, P., Abraham, S. A., and Holyoake, T. L. (2011) Hurdles toward a cure for CML: the CML stem cell. Hematology/Oncology Clinics of North America, 25(5), pp. 951-966. (doi:10.1016/j.hoc.2011.09.001)

Gallipoli, P., Shepherd, P., Irvine, D., Drummond, M., and Holyoake, T. (2011) Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study. British Journal of Haematology, 155(1), pp. 128-130. (doi:10.1111/j.1365-2141.2011.08653.x)

Pellicano, F., and Holyoake, T.L. (2011) Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks. Journal of Experimental Medicine, 208(11), pp. 2155-2158. (doi:10.1084/jem.20112087)

Helgason, G. V., Karvela, M., and Holyoake, T. L. (2011) Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. Blood, 118(8), pp. 2035-2043. (doi:10.1182/blood-2011-01-330621)

Mukhopadhyay, A., Helgason, G. V., Karvela, M., and Holyoake, T. L. (2011) Hydroxychloroquine for chronic myeloid leukemia: complete cure on the horizon? Expert Review of Hematology, 4(4), pp. 369-371. (doi:10.1586/ehm.11.34)

Pellicano, F., Simara, P., Sinclair, A., Helgason, G.V., Copland, M., Grant, S., and Holyoake, T.L. (2011) The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells. Leukemia, 25(7), pp. 1159-67. (doi:10.1038/leu.2011.67)

Schmidt, T. et al. (2011) Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1+leukemia. Cancer Cell, 19(6), pp. 740-753. (doi:10.1016/j.ccr.2011.05.007)

Allan, E.K., Holyoake, T.L., Craig, A.R., and Jorgensen, H.G. (2011) Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells. Leukemia, 25(6), pp. 985-994. (doi:10.1038/leu.2011.55)

Balabanov, S. et al. (2011) Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro. PLoS ONE, 6(4), e19164.

Iqbal, Z., Elliott, M., Watson, D.G., Holyoake, T.L., and Jorgensen, H.G. (2011) Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MS. Pakistan Journal of Pharmaceutical Sciences, 24(3), pp. 285-291.

Pellicano, F., Sinclair, A., and Holyoake, T.L. (2011) In search of CML stem cells’ deadly weakness. Current Hematologic Malignancy Reports, 6(2), pp. 82-87. (doi:10.1007/s11899-011-0085-y)

Van Etten, R.A. et al. (2011) The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues. Haematologica, 96(4), pp. 590-601. (doi:10.3324/haematol.2010.035675)

Zhou, P., Hatziieremia, S., Elliott, M. A., Scobie, L., Crossan, C., Michie, A. M., Holyoake, T. L., Halbert, G. W., and Jorgensen, H. G. (2010) Uptake of synthetic low density lipoprotein by leukemic stem cells — a potential stem cell targeted drug delivery strategy. Journal of Controlled Release, 148(3), pp. 380-387. (doi:10.1016/j.jconrel.2010.09.016)

Hopcroft, L. E.M., McBride, M. W., Harris, K. J., Sampson, A. K., McClure, J. D., Graham, D., Young, G., Holyoake, T. L., Girolami, M. A., and Dominiczak, A. F. (2010) Predictive response-relevant clustering of expression data provides insights into disease processes. Nucleic Acids Research, 38(20), pp. 6831-6840. (doi:10.1093/nar/gkq550)

Lidonnici, M.R. et al. (2010) Expression of the transcriptional repressor Gfi-1 is regulated by C/EBP  and is involved in its proliferation and colony formation-inhibitory effects in p210BCR/ABL-expressing cells. Cancer Research, 70(20), pp. 7949-7959. (doi:10.1158/0008-5472.CAN-10-1667)

Schemionek, M. et al. (2010) BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood, 115(16), pp. 3185-3195. (doi:10.1182/blood-2009-04-215376)

Helgason, V., Young, G., and Holyoake, T. (2010) Targeting chronic myeloid leukemia stem cells. Current Hematologic Malignancy Reports, 5(2), pp. 81-87. (doi:10.1007/s11899-010-0043-0)

Murray, J.A., Khanim, F.L., Hayden, R.E., Craddock, C.F., Holyoake, T.L., Jackson, N., Lumley, M., Bunce, C.M., and Drayson, M.T. (2010) Combined bezafibrate and medroxyprogesterone acetate have efficacy without haematological toxicity in elderly and relapsed acute myeloid leukaemia (AML). British Journal of Haematology, 149(1), pp. 65-69. (doi:10.1111/j.1365-2141.2009.08055.x)

Hamilton, A., Gallipoli, P., Nicholson, E., and Holyoake, T.L. (2010) Targeted therapy in haematological malignancies. Journal of Pathology, 220(4), pp. 404-418. (doi:10.1002/path.2669)

Szabo, S.M., Levy, A.R., Davis, C., Holyoake, T.L., and Cortes, J. (2010) A Multinational Study of Health State Preference Values Associated with Chronic Myelogenous Leukemia. Value in Health, 13(1), pp. 103-111. (doi:10.1111/j.1524-4733.2009.00573.x)

Heaney, N. B. et al. (2010) Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells. Blood, 115(11), pp. 2241-2250. (doi:10.1182/blood-2008-06-164582)

Irvine, D. A., Heaney, N. B., and Holyoake, T. L. (2010) Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors - A synthesis of clinical and laboratory data. Blood Reviews, 24(1), pp. 1-9. (doi:10.1016/j.blre.2009.11.002)

Jiang, X. et al. (2010) Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate. Blood, 116(12), pp. 2112-2121. (doi:10.1182/blood-2009-05-222471)

Saglio, G., Kantarjian, H., Holyoake, T., Ranganathan, A., and Cortés, J.E. (2010) Proceedings of the Third Global Workshop on Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 10(6), pp. 443-451. (doi:10.3816/CLML.2010.n.077)

Zhang, B. et al. (2010) Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell, 17(5), pp. 427-442. (doi:10.1016/j.ccr.2010.03.011)

Holyoake, T., and Nicholson, E. (2009) The Chronic Myeloid Leukemia Stem Cell. Clinical Lymphoma, Myeloma and Leukemia, 9(Suppl.), S376-S381. (doi:10.3816/CLM.2009.s.037)

Pellicano, F., Copland, M., Jorgensen, H. G., Mountford, J., Leber, B., and Holyoake, T. L. (2009) BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cβ. Blood, 114(19), pp. 4186-4196. (doi:10.1182/blood-2009-05-219550)

Davies, A. et al. (2009) Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia, 23(11), pp. 1999-2006. (doi:10.1038/leu.2009.166)

Goldman, J.M., Green, A.R., Holyoake, T.L., Jamieson, C., Mesa, R., Mughal, T., Pellicano, F., Perrotti, D., Skoda, R., and Vannucchi, A.M. (2009) Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues. Leukemia, 23(10), pp. 1708-1715. (doi:10.1038/leu.2009.142)

Drummond, M.W. et al. (2009) A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response. Leukemia, 23(6), pp. 1199-1201. (doi:10.1038/leu.2009.43)

Hatziieremia, S., Jordanides, N.E., Holyoake, T.L., Mountford, J.C., and Jorgensen, H.G. (2009) Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib. Experimental Hematology, 37(6), pp. 692-700. (doi:10.1016/j.exphem.2009.02.006)

Allan, E.K., Hamilton, A., Hatziieremia, S., Zhou, P., Jorgensen, H.G., Vigneri, P., and Holyoake, T.L. (2009) Nuclear entrapment of BCR-ABL by combining imatinib mesylate with leptomycin B does not eliminate CD34+ chronic myeloid leukaemia cells. Leukemia, 23(5), pp. 1006-1008. (doi:10.1038/leu.2008.367)

Bellodi, C. et al. (2009) Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells. Journal of Clinical Investigation, 119(5), pp. 1109-1123. (doi:10.1172/JCI35660)

Hamilton, A., Alhashimi, F., Myssina, S., Jorgensen, H. G., and Holyoake, T. L. (2009) Optimization of methods for the detection of BCR-ABL activity in Philadelphia-positive cells. Experimental Hematology, 37(3), pp. 395-401. (doi:10.1016/j.exphem.2008.11.005)

Myssina, S. et al. (2009) Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells. Experimental Hematology, 37(2), pp. 206-214. (doi:10.1016/j.exphem.2008.10.013)

Foo, J., Drummond, M.W., Clarkson, B., Holyoake, T., and Michor, F. (2009) Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib. PLoS Computational Biology, 5(9), e1000503. (doi:10.1371/journal.pcbi.1000503)

Konig, H., Copland, M., Chu, S., Jove, R., Holyoake, T. L., and Bhatia, R. (2008) Effects of Dasatinib on Src Kinase Activity and Downstream Intracellular Signaling in Primitive Chronic Myelogenous Leukemia Hematopoietic Cells. Cancer Research, 68(23), pp. 9624-9633. (doi:10.1158/0008-5472.CAN-08-1131)

Feldman, E. et al. (2008) On the use of Lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia, 22(9), pp. 1707-1711. (doi:10.1038/leu.2008.156)

Shepherd, P., Dhanapala, C., Maguire, C., White, J., Drummond, M., Holyoake, T., and Johnson, P. (2008) Successful use of national cancer registry data to monitor the effective use of imatinib for treating chronic myeloid leukaemia. Scottish Medical Journal, 53(3), pp. 8-12.

Heaney, N. B., Copland, M., Stewart, K., Godden, J., Parker, A. N., McQuaker, I. G., Smith, G. M., Crawley, C., Shepherd, P., and Holyoake, T. L. (2008) Complete molecular responses are achieved after reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukemia. Blood, 111(10), pp. 5252-5255. (doi:10.1182/blood-2007-10-118141)

Konig, H., Holtz, M., Modi, H., Manley, P., Holyoake, T., Forman, S., and Bhatia, R. (2008) Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia, 22(4), pp. 748-755. (doi:10.1038/sj.leu.2405086)

Copland, M., Pellicano, F., Richmond, L., Allan, E. K., Hamilton, A., Lee, F. Y., Weinmann, R., and Holyoake, T. L. (2008) BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood, 111(5), pp. 2843-2853. (doi:10.1182/blood-2007-09-112573)

Konig, H., Holyoake, T., and Bhatia, R. (2008) Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood, 111(4), pp. 2329-2338. (doi:10.1182/blood-2007-05-092056)

Holyoake, T., and Copland, M. (2007) LSC defenses breached by chemical arsenal. Blood, 110(13), pp. 4138-4139.

Brazma, D., Grace, C., Howard, J., Melo, J., Holyoake, T., Apperley, J., and Nacheva, E. (2007) Genomic profile of chronic myelogenous leukemia: Imbalances associated with disease progression. Genes Chromosomes and Cancer, 46(11), pp. 1039-1050. (doi:10.1002/gcc.20487)

Jorgensen, H.G., and Holyoake, T.L. (2007) Characterization of cancer stem cells in chronic myeloid leukaemia. Biochemical Society Transactions, 35(5), pp. 1347-1351. (doi:10.1042/BST0351347)

Strathdee, G. et al. (2007) Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clinical Cancer Research, 13(17), pp. 5048-5055. (doi:10.1158/1078-0432.CCR-07-0919)

Drummond, M., Balabanov, S., Holyoake, T., and Brummendorf, T. (2007) Concise review: Telomere biology in normal and leukemic hematopoietic stem cells. Stem Cells, 25(8), pp. 1853-1861. (doi:10.1634/stemcells.2007-0057)

Griffiths, S., Burthem, J., Unwin, R., Holyoake, T., Melo, J., Lucas, G., and Whetton, A. (2007) The use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia. Molecular Biotechnology, 36(2), pp. 81-89. (doi:10.1007/s12033-007-0005-5)

Heaney, N., and Holyoake, T. (2007) Therapeutic targets in chronic myeloid leukaemia. Hematological Oncology, 25(2), pp. 66-75. (doi:10.1002/hon.813)

Allan, E.K., Holyoake, T.L., Jordanides, N.E., Jorgensen, H.G., and Mountford, J.C. (2007) Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood, 109(9), pp. 4016-4019. (doi:10.1182/blood-2006-11-057521)

Halsey, C., Fisher, C., Strathdee, G., Gibson, B., Holyoake, T., Vyas, P., and Graham, G. (2007) GATA1 mutational analysis in chronic myeloid leukaemia. British Journal of Haematology, 137(4), pp. 375-376. (doi:10.1111/j.1365-2141.2007.06563.x) (PMID:17408401)

McLintock, L.A., Cook, G., Holyoake, T., Jones, B.L., Kinsey, S.E., and Jackson, G.H. (2007) High loading dose AmBisome (R) is efficacious and well tolerated in the management of invasive fungal infection in hematology patients. Haematologica: The Hematology Journal, 92(4), pp. 572-573. (doi:10.3324/haematol.10531)

Balabanov, S. et al. (2007) Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach. Blood, 109(4), pp. 1701-1711. (doi:10.1182/blood-2005-03-037648)

Copland, M., Hamilton, A., and Holyoake, T. (2007) Conventional Western blotting techniques will not reliably quantify p210 BCR-ABL - Response. Blood, 109(3), p. 1336. (doi:/10.1182/blood-2006-10-050799)

Heaney, N., and Holyoake, T. (2007) What is new in chronic myeloid leukaemia? Scottish Medical Journal, 52(1), pp. 36-41.

Graham, S., Vass, J., Holyoake, T., and Graham, G. (2007) Transcriptional analysis of quiescent and proliferating CD34+human hemopoietic cells from normal and chronic myeloid leukemia sources. Stem Cells, 25(12), pp. 3111-3120. (doi:10.1634/stemcells.2007-0250)

Pellicano, F., and Holyoake, T. (2007) Stem cells in chronic myeloid leukaemia. Cancer Biomarkers, 3(4-5), pp. 183-191.

Strathdee, G., Sim, A., Soutar, R., Holyoake, T., and Brown, R. (2007) HOXA5 is targeted by cell-type-specific CpG island methylation in normal cells and during the development of acute myeloid leukaemia. Carcinogenesis, 28(2), pp. 299-309. (doi:10.1093/carcin/bgl133)

Allan, E.K., Holyoake, T.L., and Jorgensen, H.G. (2006) Human neutrophil elastase is not a target for therapy in chronic myeloid leukaemia. Leukemia, 20(11), pp. 2054-2055. (doi:10.1038/sj.leu.2404411)

Fraser, A., Cook, G., Franklin, I., Templeton, J., Campbell, M., Holyoake, T., and Campbell, J. (2006) Immature monocytes from G-CSF-mobilized peripheral blood stem cell collections carry surface-bound IL-10 and have the potential to modulate alloreactivity. Journal of Leukocyte Biology, 80(4), pp. 862-869. (doi:10.1189/jlb.0605297)

Holyoake, T.L., Jordanides, N., Jorgensen, H.G., and Mountford, J.C. (2006) Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood, 108(4), pp. 1370-1373. (doi:10.1182/blood-2006-02-003145)

White, P. et al. (2006) A consensus on fungal polymerase chain reaction diagnosis? A United Kingdom Ireland evaluation of polymerase chain reaction methods for detection of systemic fungal infections. Journal of Molecular Diagnostics, 8(3), pp. 376-384. (doi:10.2353/jmoldx.2006.050120)

Copland, M., Hamilton, A., Eirick, L., Baird, J., Allan, E., Jordanides, N., Barow, M., Mountford, J., and Holyoake, T. (2006) Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood, 107(11), pp. 4532-4539. (doi:10.1182/blood-2005-07-2947)

Hamilton, A., Elrick, L., Myssina, S., Copland, M., Jorgensen, H.G., Melo, J.V., and Holyoake, T.L. (2006) BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry. Leukemia, 20(6), pp. 1035-1039. (doi:10.1038/sj.leu.2404189)

Jorgensen, H.G., Copland, M., Allan, E.K., Jiang, X.Y., Eaves, A., Eaves, C., and Holyoake, T.L. (2006) Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clinical Cancer Research, 12(2), pp. 626-633. (doi:10.1158/1078-0432.CCR-05-0429)

Cummins, M. et al. (2005) Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the clinical trials committee of the British Society of Blood & Marrow Transplantation (BSBMT). Bone Marrow Transplantation, 36(12), pp. 1065-1069. (doi:10.1038/sj.bmt.1705180)

Copland, M., Jorgensen, H.G., and Holyoake, T.L. (2005) Evolving molecular therapy for chronic myeloid leukaemia - are we on target? Hematology, 10(5), pp. 349-359. (doi:10.1080/10245330500234195)

Jorgensen, H.G., Allan, E.K., Mountford, J.C., Richmond, L., Harrison, S., Elliott, M.A., and Holyoake, T.L. (2005) Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate. Experimental Hematology, 33(10), pp. 1140-1146. (doi:10.1016/j.exphem.2005.05.020)

Allan, E.K., Eaves, C.J., Elliott, M.A., Godden, J.L., Graham, S.M., Holyoake, T.L., Jorgensen, H.G., Mountford, J.C., and Richmond, L. (2005) Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia, 19(7), pp. 1184-1191. (doi:10.1038/sj.leu.2403785)

Copland, M., Fraser, A., Harrison, S., and Holyoake, T. (2005) Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia. Cancer Immunology Immunotherapy, 54(4), pp. 297-306. (doi:10.1007/s00262-004-0573-1)

Deininger, M., and Holyoake, T. (2005) Can we afford to let sleeping dogs lie? Blood, 105(5), pp. 1840-1841. (doi:10.1182/blood-2004-12-4764)

Eisterer, W. et al. (2005) Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia, 19(3), pp. 435-441. (doi:10.1038/sj.leu.2403649)

Elrick, L.J., Holyoake, T.L., Jorgensen, H.G., and Mountford, J.C. (2005) Punish the parent not the progeny. Blood, 105(5), pp. 1862-1866. (doi:10.1182/blood-2004-08-3373)

Allan, E., Jordanides, N., McLintock, L., Copland, M., Devaney, M., Stewart, K., Parker, A., Johnson, P., Holyoake, T., and Jones, B. (2005) Poor performance of galactomannan and mannan sandwich enzyme-linked immunosorbent assays in the diagnosis of invasive fungal infection. British Journal of Haematology, 128(4), pp. 578-579. (doi:10.1111/j.1365-2141.2004.05333.x)

Jordanides, N., Allan, E., McLintock, L., Copland, M., Devaney, M., Stewart, K., Parker, A., Johnson, P., Holyoake, T., and Jones, B. (2005) A prospective study of real-time panfungal PCR for the early diagnosis of invasive fungal infection in haemato-oncology patients. Bone Marrow Transplantation, 35(4), pp. 389-395. (doi:10.1038/sj.bmt.1704768)

Jorgensen, H.G., Copland, M., and Holyoake, T. (2005) Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia. Cancer, 103(1), pp. 210-211. (doi:10.1002/cncr.20742)

Kilpatrick, D., Stewart, K., Allan, E., McLintock, L., Holyoake, T., and Turner, M. (2005) Successful haemopoietic stem cell transplantation does not correct mannan-binding lectin deficiency. Bone Marrow Transplantation, 35(2), pp. 179-181. (doi:10.1038/sj.bmt.1704746)

Drummond, M.W., Hoare, S.F., Monaghan, A., Graham, S.M., Alcorn, M.J., Keith, W.N., and Holyoake, T.L. (2005) Dysregulated expression of the major telomerase components in leukaemic stem cells. Leukemia, 19(3), pp. 381-389. (doi:10.1038/sj.leu.2403616)

Jorgensen, H.G., and Holyoake, T.L. (2005) From paradigm to paradox, ponder anew the CML stem cell. Bloodmed Com,

Drummond, M., Lennard, A., Brummendorf, T., and Holyoake, T. (2004) Telomere shortening correlates with prognostic score at diagnosis and proceeds rapidly during progression of chronic myeloid leukemia. Leukemia and Lymphoma, 45(9), pp. 1775-1781. (doi:10.1080/10428190410001693542)

Harrison, S., Johnson, P., and Holyoake, T. (2004) The Scotland Leukaemia Registry audit of incidence, diagnosis and clinical management of new patients with chronic myeloid leukaemia in 1999 and 2000. Scottish Medical Journal, 49(3), pp. 87-90.

Osborne, W., Holyoake, T., McQuaker, I., and Parker, A. (2004) Fatal peripheral neuropathy following FLA chemotherapy. Clinical and Laboratory Haematology, 26(4), pp. 295-296. (doi:10.1111/j.1365-2257.2004.00613.x)

McLintock, L., Holyoake, T., and Jones, B. (2004) Published rather than proposed definitions for invasive fungal infection must be applied to allow standardization in clinical trials. Clinical Infectious Diseases, 38(11), pp. 1648-1649. (doi:10.1086/421029)

McLintock, L., Jordanides, N., Allan, E., Copland, M., Stewart, K., Parker, A., Devaney, M., Holyoake, T., and Jones, B. (2004) The use of a risk group stratification in the management of invasive fungal infection: a prospective validation. British Journal of Haematology, 124(3), pp. 403-404. (doi:10.1046/j.1365-2141.2003.04794.x)

Drummond, M., Marin, D., Clark, R., Byrne, J., Holyoake, T., and Lennard, A. (2003) Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission. British Journal of Haematology, 123(3), pp. 479-483. (doi:10.1046/j.1365-2141.2003.04599.x)

Kilpatrick, D.C. et al. (2003) No strong relationship between mannan binding lectin or plasma ficolins and chemotherapy-related infections. Clinical and Experimental Immunology, 134(2), pp. 279-284. (doi:10.1046/j.1365-2249.2003.02284.x)

Drummond, M., and Holyoake, T. (2003) Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer, 98(8), pp. 1776-1777. (doi:10.1002/cncr.11715)

Jorgensen, H.G., Allan, E.K., Jiang, X., Liakopoulou, E., Richmond, L., Eaves, C.J., Eaves, A.C., and Holyoake, T.L. (2003) Stage-specific alterations in serum levels of G-CSF in chronic myeloid leukaemia. Leukemia, 17(7), pp. 1430-1432. (doi:10.1038/sj.leu.2402967)

Paterson, S.C., Smith, K.D., Holyoake, T.L., and Jorgensen, H.G. (2003) Is there a cloud in the silver lining for imatinib? British Journal of Cancer, 88(7), pp. 983-987. (doi:10.1038/sj.bjc.6600828)

Chee, Y., Vickers, M., Stevenson, D., Holyoake, T., and Culligan, J. (2003) Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones. Leukemia, 17(3), pp. 634-635. (doi:10.1038/si.leu.2402842)

Drummond, A., Micallef-Eynaud, P., Douglas, W., Murphy, J., Hay, I., Holyoake, T., and Drummond, M. (2003) A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec (R)). British Journal of Haematology, 120(5), pp. 911-913. (doi:10.1046/j.1365-2141.2003.04151_4.x)

Drummond, M., Lush, C., Vickers, M., Reid, F., Kaeda, J., and Holyoake, T. (2003) Imatinib mesylate-induced molecular remission of Philadelphia chromosome-positive myelodysplastic syndrome. Leukemia, 17(2), pp. 463-465. (doi:10.1038/sj.leu.2402814)

Clark, A.D., Jorgensen, H.G., Mountford, J.C., and Holyoake, T.L. (2003) Isolation and therapeutic potential of human haemopoietic stem cells. Cytotechnology, 41(2-3), pp. 111-131. (doi:10.1023/A:1024822722285)

Drummond, M., Hendry, L., Maher, E., and Holyoake, T. (2002) BCR-ABL fish monitoring of CML: A survey of current UK practice. British Journal of Haematology, 119(1), pp. 272-273. (doi:10.1046/j.1365-2141.2002.38802.x)

Richmond, L., Alcorn, M., Pearson, C., Cameron, G., Thomas, T., Eaves, C., Eaves, A., and Holyoake, T. (2002) CML leukapheresis products can be enriched for CD34(+) cells and simultaneously depleted of CD15(+) cells using a simple Ab cocktail. Cytotherapy, 4(5), pp. 407-413. (doi:10.1080/146532402320775991)

Jorgensen, H.G., Elliott, M., Paterson, S., Holyoake, T.L., and Smith, K. (2002) Further observations on the debated ability of AGP to bind imatinib - Response. Blood, 100(1), pp. 368-369.

Goldman, J., Apperley, J., Clark, R., Green, T., Holyoake, T., O'Brien, S., and Shepherd, P. (2002) Not So Nice for CML. Lancet, 359(9322), p. 2036. (doi:10.1016/S0140-6736(02)08796-2)

Holyoake, T., Jiang, X., Drummond, M., Eaves, A., and Eaves, C. (2002) Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia. Leukemia, 16(4), pp. 549-558. (doi:10.1038/sj/leu/2402444)

Pottinger, B., Walker, M., Campbell, M., Holyoake, T., Franklin, I., and Cook, G. (2002) The storage and re-infusion of autologous blood and BM as back-up following failed primary hematopoietic stem-cell transplantation: a survey of European practice. Cytotherapy, 4(2), pp. 127-135. (doi:10.1080/146532402317381839)

Graham, S.M., Jorgensen, H.G., Allan, E.K., Pearson, C., Alcorn, M.J., Richmond, L., and Holyoake, T.L. (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood, 99(1), pp. 319-325. (doi:10.1182/blood.V99.1.319)

Jorgensen, H.G., Elliott, M.A., Allan, E.K., Carr, C.E., Holyoake, T.L., and Smith, K.D. (2002) α1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. Blood, 99(2), pp. 713-715. (doi:10.1182/blood.V99.2.713)

Jorgensen, H.G., and Holyoake, T.L. (2001) A comparison of normal and leukemic stem cell biology in chronic myeloid leukemia. Hematological Oncology, 19(3), pp. 89-106. (doi:10.1002/hon.667.abs)

Holyoake, T., Freshney, M., Samuel, K., Ansell, J., Watson, G., Wright, E., Graham, G., and Pragnell, I. (2001) In vivo expansion of the endogenous B-cell compartment stimulated by radiation and serial bone marrow transplantation induces B-cell leukaemia in mice. British Journal of Haematology, 114(1), pp. 49-56. (doi:10.1046/j.1365-2141.2001.02903.x)

Drummond, M., and Holyoake, T. (2001) Tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia: so far so good? Blood Reviews, 15(2), pp. 85-95. (doi:10.1054/blre.2001.0152)

Holyoake, T. (2001) Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: Lessons to be learned from the laboratory. British Journal of Haematology, 113(1), pp. 11-23. (doi:10.1046/j.1365-2141.2001.02558.x)

Campbell, J., Cook, G., and Holyoake, T. (2001) Evolution of bone marrow transplantation - the original immunotherapy. Trends in Immunology, 22(2), pp. 88-92. (doi:10.1016/S1471-4906(00)01857-3)

Holyoake, T.L., Jiang, X.Y., Jorgensen, H.G., Graham, S., Alcorn, M.J., Laird, C., Eaves, A.C., and Eaves, C.J. (2001) Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood, 97(3), pp. 720-728. (doi:10.1182/blood.V97.3.720)

Glimm, H., Eisterer, W., Lee, K., Cashman, J., Holyoake, T., Nicolini, F., Shultz, L., von Kalle, C., and Eaves, C. (2001) Previously undetected human hematopoietic cell populations with short-term repopulating activity selectively engraft NOD/SCID-beta 2 microglobulin-null mice. Journal of Clinical Investigation, 107(2), pp. 199-206. (doi:10.1172/JCI11519)

Book Sections

Hopcroft, L. E. M., Calderhead, B., Gallipoli, P., Holyoake, T. L., and Girolami, M. A. (2015) Bayesian inference for model selection: an application to aberrant signalling pathways in chronic myeloid leukaemia. In: Markowetz, F. and Boutros, M. (eds.) Systems Genetics: Linking Phenotypes to Genotypes. Series: Cambridge series in systems genetics. Cambridge University Press, pp. 161-190. ISBN 9781107013841

Abraham, S., Hopcroft, L., Bhatia, R., Koschmieder, S., Whetton, A., and Holyoake, T. (2014) Models to study chronic myeloid leukemia cancer stem cells. In: Rajasekhar, V. (ed.) Cancer Stem Cells. Wiley-Blackwell. ISBN 9781118356166 (doi:10.1002/9781118356203.ch9)

Copland, M., Michie, A. M., and Holyoake, T. L. (2009) Stem cells in Leukemia and other hematological malignancies. In: Majumder, S. (ed.) Stem Cells and Cancer. Springer New York: New York, NY, pp. 111-136. ISBN 9780387896106 (doi:10.1007/978-0-387-89611-3_5)

Brummendorf, T., Rufer, N., Holyoake, T., Maciejewski, J., Barnett, M., Eaves, C., Eaves, A., Young, N., and Lansdorp, P. (2001) Telomere length dynamics in normal individuals and in patients with hematopoietic stem cell-associated disorders. In: Orlic, D., Brummendorf, T., Sharkis, S. and Kanz, L. (eds.) Hematopoietic Stem Cells 2000 Basic And Clinical Sciences. Series: Annals Of The New York Academy Of Sciences (938). New York Academy of Sciences: New York, pp. 293-304. ISBN 1-57331-295-9

Conference Proceedings

Abraham, S., Hopcroft, L., Carrick, E., Williamson, A., Pierce, A., Cassels, J., Pellicano, F., Whetton, A., and Holyoake, T. L. (2013) p53 and c-Myc are critical signaling hubs that maintain chronic myeloid leukemia. In: 55th American Society of Hematology Annual Meeting and Exposition, New Orleans, LA, USA, 7-10 Dec 2013, p. 1465.

This list was generated on Sun Dec 4 20:31:06 2016 GMT.